US20120190730A1 - Targeting cells with altered microrna expression - Google Patents

Targeting cells with altered microrna expression Download PDF

Info

Publication number
US20120190730A1
US20120190730A1 US11/916,276 US91627606A US2012190730A1 US 20120190730 A1 US20120190730 A1 US 20120190730A1 US 91627606 A US91627606 A US 91627606A US 2012190730 A1 US2012190730 A1 US 2012190730A1
Authority
US
United States
Prior art keywords
hsa
mir
cell
nucleic acid
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/916,276
Other languages
English (en)
Inventor
Michael Zenon Michael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTER
Vimar SpA
Original Assignee
Vimar SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36928649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20120190730(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vimar SpA filed Critical Vimar SpA
Priority claimed from PCT/AU2006/000750 external-priority patent/WO2006128245A1/en
Assigned to SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTER reassignment SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MICHAEL, MICHAEL ZENON
Publication of US20120190730A1 publication Critical patent/US20120190730A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B3/00—Line transmission systems
    • H04B3/54—Systems for transmission via power distribution lines
    • H04B3/56—Circuits for coupling, blocking, or by-passing of signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B3/00—Line transmission systems
    • H04B3/54—Systems for transmission via power distribution lines
    • H04B3/548—Systems for transmission via power distribution lines the power on the line being DC
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B2203/00—Indexing scheme relating to line transmission systems
    • H04B2203/54—Aspects of powerline communications not already covered by H04B3/54 and its subgroups
    • H04B2203/5462—Systems for power line communications
    • H04B2203/547—Systems for power line communications via DC power distribution

Definitions

  • the present invention relates to a method of modulating the development of a cell with altered microRNA activity, and to a method of preventing and/or treating a disease, condition or state associated with altered microRNA activity.
  • the present invention also relates to nucleic acids having a binding site for a microRNA, cells and animals including such nucleic acids, and compositions including the nucleic acids.
  • Targeted gene expression is one of the most difficult and important goals in the development of effective therapies for a variety of disorders, including cell proliferative disorders such as cancer.
  • the ultimate aim of such therapies is the provision of controlled, sustained, and site-specific expression of a therapeutic agent such that surrounding healthy tissue remains relatively unaffected by the effects of the therapeutic agent.
  • tissue specific promoters may be adequate to achieve specific expression of an agent in some target tissues, for diseases such as cancer they have proved to be of less value as non-diseased cells may also express from the promoter. Accordingly, there is a need to identify new methods of targeting expression of therapeutic nucleic acids.
  • miRNAs RNA molecules known as regulating gene expression in variety of eukaryotic systems.
  • miRNAs coordinate the transitions between stages of larval development by regulating the translation of heterochromic genes.
  • a specific miRNA in Arabidopsis has been shown to direct the cleavage of transcripts encoding several putative transcription factors.
  • the Drosophila bantam gene encodes a miRNA that regulates cell proliferation and the proapoptotic gene hid. More recently, human miR143 has been shown to regulate adipocyte differentiation.
  • miRNAs are formed from larger transcripts that fold to produce hairpin structures and serve as substrates for the Dicer family of RNase III enzymes. They share this process with an experimental system, RNA interference (RNAi), which may be used to silence the expression of endogenous genes in eukaryotic cells.
  • RNAi RNA interference
  • the products of Dicer cleavage are short dsRNA molecules, one strand of which is retained in a ribonucleoprotein complex called the RNA-induced silencing complex (RISC).
  • RISC RNA-induced silencing complex
  • the retained RNA acts as a guide to target this complex to a complementary mRNA sequence which is inactivated either by cleavage or translational interference, depending on the degree of complementarity between the miRNA and its target.
  • the present invention relates to a method of modulating the development of cells with altered microRNA levels, and arises from the recognition that some diseased cells have altered expression levels of endogenous microRNAs and that expression of therapeutic nucleic acids may be effectively targeted to such cells by exploiting the altered expression of the microRNAs in these cells.
  • the present invention provides a method of modulating development of a cell, the method including the step of introducing into the cell a nucleic acid with the capacity to modulate development of the cell, the nucleic acid including a target site for binding of a microRNA, wherein the activity and/or concentration of the microRNA in the cell results in a level of activity and/or concentration of the nucleic acid in the cell sufficient to modulate development of the cell.
  • the present invention also provides a nucleic acid with the capacity to modulate development of a cell, the nucleic acid including a binding site for a microRNA.
  • the present invention also provides a nucleic acid including a non-naturally occurring binding site for a microRNA that is differentially expressed and/or has differential activity.
  • the present invention also provides a cancerous cell including an exogenous nucleic acid including a binding site for a microRNA, wherein the cancerous cell has a reduced activity and/or concentration of the microRNA as compared to a similar non-cancerous cell.
  • the present invention also provides an animal including cancerous cells, the cancerous cells including an exogenous nucleic acid including a target site for binding of a microRNA.
  • the present invention also provides a method of preventing and/or treating a disease, condition or state associated with target cells in a subject, the method including the step of introducing into cells in the subject a nucleic acid with the capacity to modulate development of a cell, the nucleic acid including a target site for binding of the microRNA, wherein the activity of the microRNA in the target cells results in a level of activity of the nucleic acid sufficient to modulate development of the target cells in the subject.
  • the present invention also provides a method of detecting altered microRNA activity and/or concentration in a cancerous or pre-cancerous cell, the method including the steps of:
  • the present invention also provides a method of modulating the concentration of a nucleic acid expressed in a cancerous cell, the cancerous cell having an altered activity and/or concentration of a microRNA as compared to a similar non-cancerous cell, the method including the step of introducing a target site for binding of the microRNA into the nucleic acid to be expressed in the cell.
  • the present invention arises from the recognition that many cells, including cancerous cells, have altered expression levels of endogenous microRNAs, and that expression of therapeutic nucleic acids may be more effectively targeted to such cells by exploiting the altered expression of the microRNAs in these cells.
  • microRNAs are modulated during differentiation of cells or during their normal developmental programme, and accordingly, expression of nucleic acids may also be targeted to these cells at specific times in their developmental programme and/or at times when the level of the microRNAs changes.
  • development as used throughout the specification in relation to the development of a cell is to be understood to mean the continuance of a cell in its current state or the continuance of a cell in its normal developmental and/or metabolic program.
  • modulation of the development of a cell may, for example, result in an inhibition or cessation of cell growth, cell death, or an alteration in the normal developmental pathway that a cell undergoes.
  • modulation of the development of a cell may result, for example, in increased cell survival or rescue, or increased cell proliferation.
  • module or variants thereof as used throughout the specification is to be understood to mean any alteration (increase or decrease) in the activity of a process. For example, alteration may result in activation of a process, inhibition of a process, a change in the timing of a process or a change in probability that a process may occur.
  • nucleic acid as used throughout the specification is to be understood to mean to any oligonucleotide or polynucleotide.
  • the nucleic acid may be DNA or RNA and may be single stranded or double stranded.
  • the nucleic acid may be any type of nucleic acid, including a nucleic acid of genomic origin, cDNA origin (ie derived from a mRNA), derived from a virus, or of synthetic origin. It will be appreciated that a nucleic acid with the capacity to modulate development of a cell is a nucleic acid that in a particular cell either inhibits or promotes development of the cell.
  • an oligonucleotide or polynucleotide may be modified at the base moiety, sugar moiety, or phosphate backbone, and may include other appending groups to facilitate the function of the nucleic acid.
  • the oligonucleotide or polynucleotide may be modified at any position on its structure with constituents generally known in the art.
  • an oligonucleotide may include at least one modified base moiety which is selected from the group including 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyliydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta D-mannosylqueosine,
  • the oligonucleotide or polynucleotide may also include at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.
  • the oligonucleotide or polynucleotide may include at least one modified phosphate backbone, such as a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or any analogue thereof.
  • subject as used throughout the specification is to be understood to mean any multicellular organism, including an animal or human subject.
  • the subject may be a mammal such as a primate, a livestock animal (eg. A horse, a cow, a sheep, a pig, a goat), a companion animal (eg. a dog, a cat), a laboratory test animal (eg. a mouse, a rat, a guinea pig, a bird), an animal of veterinary significance, or an animal of economic significance.
  • variant as used throughout the specification is to be understood to mean an amino acid sequence of a polypeptide or protein that is altered by one or more amino acids.
  • the variant may have “conservative” changes, wherein a substituted amino acid has similar structural or chemical properties to the replaced amino acid (e.g., replacement of leucine with isoleucine).
  • a variant may also have “non-conservative” changes (e.g., replacement of a glycine with a tryptophan) or a deletion and/or insertion of one or more amino acids.
  • the term also includes within its scope any insertions/deletions of amino acids for a particular polypeptide or protein.
  • a “functional variant” will be understood to mean a variant that retains the functional capacity of a reference protein or polypeptide.
  • FIG. 1 shows in the top panel the stem-loop structure of the hsa-miR-143 precursor and the nucleotide sequence of the mature hsa-miR-143 microRNA.
  • the bottom panel shows the stem-loop structure of the hsa-miR-145 precursor and the nucleotide sequence of the mature hsa-miR-145 microRNA.
  • FIG. 2 shows EGFP fluorescence (three days post-transfection) from HeLa cells cotransfected with 0.1 ⁇ g EGFP/RICS-miR145 target sequence expression vector (pMM095) and varying levels of pri-miR145 (single—pMM109, and tandem—pMM107) expression plasmids, antisense (A/S; pMM106) and empty vector controls (pcDNA3.1). Data are representative of two experiments.
  • FIG. 3 shows the map for plasmid pMM043.
  • FIG. 4 shows the map for plasmid pMM095.
  • the nucleotide sequence of pMM095 is provided in the sequence listing and is designated SEQ ID NO. 153.
  • FIG. 5 shows the map for plasmid pMM105.
  • the nucleotide sequence of pMM105 is provided in the sequence listing and is designated SEQ ID NO. 154.
  • FIG. 6 shows the map for plasmid pMM106.
  • the nucleotide sequence of pMM106 is provided in the sequence listing and is designated SEQ ID NO. 155.
  • FIG. 7 shows the map for plasmid pMM107.
  • the nucleotide sequence of pMM107 is provided in the sequence listing and is designated SEQ ID NO. 156.
  • FIG. 8 shows the map for plasmid pMM109.
  • the nucleotide sequence of pMM109 is provided in the sequence listing and is designated SEQ ID NO. 157.
  • FIG. 9 shows the map for plasmid pMM-TK/miRTarg.
  • the nucleotide sequence of pMM-TK/miRTarg is provided in the sequence listing and is designated SEQ ID NO. 158.
  • FIG. 10 shows the map for plasmid pMM-CD/miRTarg.
  • the nucleotide sequence of pMM-CD/miRTarg is provided in the sequence listing and is designated SEQ ID NO. 159.
  • FIG. 11 shows in the top panel real time RT-PCR quantitation of relative pri-miR145 levels 24 h post Dox-induction.
  • the lower panel shows accumulation of mature miR145 in HeLa Tet-On/pMM110d line, following 24 h incubation in 1 ⁇ g/mL doxycycline, by Northern analysis: 20 ⁇ g total RNA/sample, 15% denaturing PAGE minigel. The ethidium bromide stained gel is shown to compare loading of samples.
  • FIG. 12 shows the effect of increasing miRNA target sequences in the 3′UTR of a transgene.
  • Cells of the stable pMM110 transgenic HeLa Tet On cell line, HTO110e were grown in the presence, or absence, of 2 ⁇ g doxycycline/mL medium and FuGene6-transfected, one after plating, with 80 ng plasmid.
  • the present invention provides a method of modulating development of a cell, the method including the step of introducing into the cell a nucleic acid with the capacity to modulate development of the cell, the nucleic acid including a target site for binding of a microRNA, wherein the activity and/or concentration of the microRNA in the cell results in a level of activity and/or concentration of the nucleic acid in the cell sufficient to modulate development of the cell.
  • the present invention arises from the recognition that some diseased cells have altered expression levels of endogenous microRNAs, and that expression of nucleic acids may be effectively targeted to these cells by exploiting the altered expression of the microRNAs in the cells.
  • the present invention has application in fields such as genetic engineering and therapeutic gene transfer.
  • the present invention is suitable for example for targeting expression of a cytotoxic nucleic acid to a diseased cell so as to ablate the cell, or alternatively, for targeting expression of a therapeutic nucleic acid to a diseased cell to improve one or more characteristics of the cell (eg for gene therapy purposes).
  • miRNAs are produced from hairpin precursor (pre-miRNAs) that are cleaved to the shorter mature miRNA, as shown in FIG. 1 .
  • pre-miRNAs hairpin precursor
  • the present invention may be used, for example, to modulate the development of cells having reduced expression of the miR-143 or miR-145 microRNAs.
  • the alteration in the level and/or activity of the one or more microRNAs in the cell may be a constitutive alteration, or alternatively, may be an alteration that occurs at a specific point(s) in the developmental programme of the cell.
  • the present invention is suitable for modulating development of a cancer cell that shows a reduced constitutive expression and/or activity of a particular miRNA, for modulating development of a cell infected with a virus which causes altered expression and/or activity of a miRNA, or for modulating development of an embryonic or adult stem cell that modulates the activity of a specific miRNA at specific stages of its developmental programme.
  • Confirmation that a cell has an altered activity and/or expression of a specific miRNA may be achieved by a suitable method known in the art, such as Northern analysis, reverse transcription PCR (RT-PCR) or RNase protection.
  • a suitable method known in the art such as Northern analysis, reverse transcription PCR (RT-PCR) or RNase protection.
  • confirmation that a cell has an altered activity and/or expression of a specific miRNA may be achieved by way of expression of a reporter gene linked to a target site for the particular miRNA.
  • the level of expression of the reporter gene will inversely reflect the activity and/or expression level of the miRNA in the cell.
  • a target site may be cloned into the 3′UTR of GFP, and the construct introduced into the cell.
  • Methods for the cloning of nucleic acid sequences are as described in Sambrook, J, Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual 2nd. ed. Cold Spring Harbor Laboratroy Press, New York. (1989).
  • a reduced activity and/or expression of a miRNA may be correlated with a disease, condition or state.
  • cancerous cells often have a reduced level of one or more specific miRNAs.
  • a reduced level of miRNA activity and/or expression is associated with the progression of a normal cell to a cancerous cell.
  • the cell in this form of the present invention may be a cancerous cell or a pre-cancerous cell.
  • cancerous cells that show a reduced activity and/or expression of a miRNA include colorectal cancer cells, lung cancer cells, thymus cancer cells, bladder cancer cells, breast cancer cells and prostate cancer cells.
  • cancerous cells generally include cells associated with the cancers such as bladder cancer, bone cancer, brain tumours, breast cancer, cervical cancer, colorectal cancer including cancer of the colon, rectum, anus, and appendix, cancer of the esophagus, Hodgkin's disease, kidney cancer, cancer of the larynx, leukemia, liver cancer, lung cancer, lymphoma, melanoma, moles and dysplastic nevi, multiple myeloma, muscular cancer, non-Hodgkin's lymphoma, oral cancer, ovarian cancer, cancer of the pancreas, prostate cancer, skin cancer, stomach cancer, testicular cancer, teratoma, thyroid cancer, and cancer of the uterus.
  • the present invention also includes pre-cancerous cells, including for example, pre-cancerous cells associated with the aforementioned cancers.
  • the cell in the various forms of the present invention is cancerous cell from a colorectal cancer or colorectal polyp, including a cancerous cell from a colorectal adenocarcinoma or an adenomatous polyp.
  • the cell in the various forms of the present invention may also be for example an embryonic stem (ES) cell or an adult stem cell.
  • ES embryonic stem
  • microRNAs have been identified in the mouse for which expression is repressed as the ES cells differentiate into embryoid bodies and is undetectable in adult organs, indicating that these miRNAs may have a role in the maintenance of the pluripotent cell state and in the regulation of early mammalian development.
  • haemopoietic cells including haemopoietic precursor cells, adipocytes, chronic lymphocytic B cells, neuronal cells, sperm cells or sperm producing cells, pancreatic endocrine cells including pancreatic islet cells, and virally infected cells including EBV, HIV, Hepatitis and Herpes infected cells.
  • the cell for which development is modulated in the various forms of the present invention may be an isolated cell in vitro, or a cell present in a biological system such as a cell in an organ or tissue, or a cell present in an entire organism (eg animal or human subject).
  • a biological system such as a cell in an organ or tissue, or a cell present in an entire organism (eg animal or human subject).
  • biological system is to be understood to mean any multi-cellular system, and includes isolated groups of cells to whole organisms.
  • the present invention may be used to modulate the development of a target cell in a biological system.
  • the present invention provides a method of modulating development of a target cell in a biological system, the method including the step of introducing into a target cell in the biological system a nucleic acid with the capacity to modulate development of the cells in the biological system, the nucleic acid including a target site for binding of a microRNA, wherein the activity and/or concentration of the microRNA in the target cell results in a level of activity and/or concentration of the nucleic acid in the target cell sufficient to modulate the development of the target cell.
  • the biological system is an animal or human subject, including an animal or human that is susceptible to, or suffering from, a disease, condition or state associated with altered microRNA activity and/or expression.
  • the present invention is therefore suitable for preventing and/or treating a disease, condition or state associated with target cells having an altered activity of a microRNA in a subject.
  • the present invention provides a method of preventing and/or treating a disease, condition or state associated with target cells in a subject, the method including the step of introducing into cells in the subject a nucleic acid with the capacity to modulate development of a cell, the nucleic acid including a target site for binding of the microRNA, wherein the altered activity of the microRNA in the target cells results in a level of activity of the nucleic acid sufficient to modulate development of the target cells in the subject.
  • diseases, conditions or states associated with altered microRNA activity and/or expression in the various forms of the present invention are as previously discussed, including cancers such as colorectal cancer, lung cancer, thymus cancer, bladder cancer, breast cancer and prostate cancer; human B cell chronic lymphocytic leukemia; B cell (Burkitt) Lymphoma; disorders of pancreatic endocrine cells such as diabetes; diseases and conditions associated with virally infection of cells such as EBV, HIV, Hepatitis and Herpes infected cells; 5q-myelodysplastic syndrome (macrocytic anaemia); diseases and conditions associated with haemopoietic dysfunction; autoimmune and inflammatory diseases (eg Crohn's); fragile X mental retardation; Di George syndrome; Wilms tumour; a disease or condition associated with adipocyte dysfunction; a disease that can be treated with embryonic or adult stem cells; and a disease or condition associated with sperm producing cells.
  • cancers such as colorectal cancer, lung cancer, thymus cancer,
  • nucleic acid effective to provide a therapeutic or desired effect will be introduced/administered to the cell, biological system or subject in the various relevant forms of the present invention.
  • the present invention may be used to either inhibit the development of target cells by use of a nucleic acid that inhibits the development of target cells, or alternatively, to promote the development of target cells by the use of a nucleic acid that promotes the development of target cells.
  • the present invention may be used to selectively ablate or rescue cells. Methods for determining whether the development of a cell have been inhibited or promoted are known in the art.
  • the development of a cell may be inhibited.
  • the nucleic acid introduced into the cell will have the capacity to inhibit development of the cell.
  • the nucleic acid will include one or more target sites for binding of one or more miRNAs, a reduction in activity and/or expression of the one or more miRNAs in a cell will result in an increased expression of the nucleic acid (as compared to a similar cell which does not have a reduced activity of the one or more miRNAs) and consequently result in a level of expression of the nucleic acid sufficient to inhibit development of the cell.
  • the present invention provides a method of inhibiting development of a cell, the cell having a reduced activity and/or concentration of a microRNA, the method including the step of introducing into the cell a nucleic acid with the capacity to inhibit development of the cell, the nucleic acid including a target site for binding of the microRNA, wherein the reduced activity and/or concentration of the microRNA in the cell results in a level of activity and/or concentration of the nucleic acid in the cell sufficient to inhibit development of the cell.
  • the nucleic acid with the capacity to inhibit development of a cell is a nucleic acid with cytotoxic or cytostatic activity, or a nucleic acid encoding a suicide gene.
  • the introduction of such a nucleic acid including one or more target sites for binding of one or more miRNAs into cells will result in an inhibition of development in those cells that have a reduced activity and/or expression of the one or more miRNAs.
  • the miRNAs will act to reduce the expression of the nucleic acid sufficiently that cell development is not inhibited, or at least less inhibited than the cells with the reduced activity and/or expression of the miRNA.
  • the present invention allows the selective inhibition of cells with a reduced activity and/or expression of a specific miRNA.
  • the present invention may be used to selectively ablate target cells with a reduced activity and/or expression of a specific miRNA.
  • cytotoxic or suicide genes are generally as described in Greco and Dachs (2001) J Cell Physiol. 187(1):22-36 and include herpes simplex thymidine kinase [NC — 001798:c48000-46870 (HSV2 genome)] [gi
  • aeruginosa carboxypeptidase G2 [AE004706.1: 3474-4712], horseradish peroxidase [X57564] [gi
  • the nucleic acid with the capacity to inhibit development of the cell is selected from one of the group consisting of herpes simplex thymidine kinase, a purine nucleoside phosphorylase and a cytosine deaminase.
  • the nucleotide sequence of the HSV thymidine kinase gene is designated SEQ ID NO. 151.
  • the nucleotide sequence of E. coli cytosine deaminase is designated SEQ ID NO. 152.
  • the initiation codon is modified from GTG to ATG for mammalian expression constructs.
  • plasmid encoding the HSV thymidine kinase gene and the miRNA target sequence for miR-145 is plasmid pMM-TK/miR-Targ, which is shown in FIG. 9 .
  • the nucleotide sequence of this plasmid is designated SEQ ID NO.158.
  • plasmid encoding the E. coli cytosine deaminase and the miRNA target sequence for miR-145 is plasmid pMM-CD/miR-Targ, which is shown in FIG. 10 .
  • the nucleotide sequence of this plasmid is designated SEQ ID NO.159.
  • the present invention allows the development of a cell to be promoted.
  • the nucleic acid introduced into the cell will have the capacity to promote development of the cell.
  • the nucleic acid will include one or more target sites for binding of one or more miRNAs, a reduction in activity and/or expression of the one or more miRNAs will result in an increased expression of the nucleic acid (as compared to a similar cell which does not have a reduced activity of the one or more miRNAs) and consequently result in a level of expression of the nucleic acid sufficient to promote development of the cell.
  • the present invention provides a method of promoting development of a cell, the cell having a reduced activity and/or concentration of a microRNA, the method including the step of introducing into the cell a nucleic acid with the capacity to promote development of the cell, the nucleic acid including a target site for binding of the microRNA, wherein the reduced activity and/or concentration of the microRNA in the cell results in a level of activity and/or concentration of the nucleic acid in the cell sufficient to promote development of the cell.
  • GM-CSF granulocyte macrophage-colony stimulating factor
  • G-CSF human: NM — 000759
  • NM — 172219 human NM — 172220
  • Interleukin 11 human: NM — 000641
  • Tumour Necrosis Factor alpha human: NM — 000594
  • a cytokine gene the introduction of a nucleic acid encoding a cytokine into cells will result in a promotion of development in cells that have a reduced activity and/or expression of the one or more miRNAs.
  • the cells will be susceptible to the effects of the cytokine.
  • the miRNAs will act to reduce the expression of the nucleic acid sufficiently that cell development is not promoted, or at least less promoted to an extent that is less than the cells with the reduced activity and/or expression of the miRNA.
  • the present invention allows the selective promotion of development of target cells with a reduced activity and/or expression of a specific miRNA.
  • the expression of the nucleic acid with the capacity to modulate development of a cell will require various regulatory elements known in the art for the expression of the inserted nucleic acids in particular cell types, such as promoters for driving the expression of an inserted nucleic acid in a particular cell, poly A signals for efficient polyadenylation of mRNA transcribed from inserted nucleic acids, or other regulatory elements to control translation, transcription or mRNA stability.
  • the promoter driving the expression may be a constitutive promoter, an inducible promoter or a cell or tissue specific promoter.
  • Constitutive mammalian promoters include hypoxanthine phosphoribosyl transferase (HPTR), adenosine deaminase, pyruvate kinase, phosphoglycerate kinase (which has intrinsic bi-directional activity) and ⁇ -actin.
  • HPTR hypoxanthine phosphoribosyl transferase
  • adenosine deaminase adenosine deaminase
  • pyruvate kinase pyruvate kinase
  • phosphoglycerate kinase which has intrinsic bi-directional activity
  • Exemplary viral promoters which function constitutively in eukaryotic cells include promoters from the simian virus, papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of moloney leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus.
  • Inducible promoters include synthetic promoters regulated by the TetO/TetR system and inducible promoters such as metallothionein promoter, which may be used to induce transcription in the presence of certain metal ions. Other inducible promoters are known in the art.
  • tissue-specific promoter will depend upon the particular cell type.
  • promoters that allow expression in colon cancer cells include the regulatory sequences of human carcinoembryonic antigen (CEA) [accession:U17131; gi/967132].
  • microRNAs that are correlated with human cancer, or the progression of a normal cell to a cancerous cell in humans, are as follows (5′ to 3′):
  • hsa-let-7a-1 pre-miRNA precursor (SEQ ID NO. 1) ugggaugagguaguagguuguauaguuuuagggucacacccaccacugggagauaacuauacaau cuacugucuuuccua hsa-let-7 mature miRNA: (SEQ ID NO. 2) ugagguaguagguuguauaguu hsa-let-7a-2 pre-miRNA precursor: (SEQ ID NO.
  • ugagguaguagguuguauaguu hsa-let-7b pre-miRNA precursor (SEQ ID NO. 7) cggggugagguaguagguugugugguuucagggcagugauguugccccucggaagauaacuauac aaccuacugccuucccug hsa-let-7b mature miRNA: (SEQ ID NO. 8) ugagguaguagguugugugguu hsa-let-7c pre-miRNA precursor: (SEQ ID NO.
  • gcauccggguugagguaguagguuguaugguuuagaguuacacccugggaguuaacuguacaacc uucuagcuuuccuuggagc hsa-let-7c mature miRNA (SEQ ID NO. 10) ugagguaguagguuguaugguu hsa-let-7f-1 pre-miRNA precursor: (SEQ ID NO. 11) ucagagugagguaguagauuguauaguugugggguagugauuuuacccuguucaggagauaacua uacaaucuauugccuucccuga hsa-let-7f mature miRNA: (SEQ ID NO.
  • ugagguaguagauuguauaguu hsa-let-7f-2 pre-miRNA precursor (SEQ ID NO. 13) ugugggaugagguaguagauuguauaguuuuagggucauaccccaucuuggagauaacuauacag ucuacugucuuucccacg hsa-let-7f mature miRNA: (SEQ ID NO. 14) ugagguaguagauuguauaguu hsa-mir-10b pre-miRNA precursor: (SEQ ID NO.
  • microRNA that is associated with the regulation of insulin secretion is hsa-miR-375:
  • hsa-mir-375 pre-miRNA precursor (SEQ ID NO. 160) ccccgcgacgagccccucgcacaaaccggaccugagcguuuuguucguucggcucgcgugaggc hsa-miR-375 mature miRNA: (SEQ ID NO. 161) uuuguucguucggcucgcguga
  • hsa-miR-181b-1 is likely to be involved in haemopoiesis (B lineage cell differentiation):
  • hsa-mir-181b-1 pre-miRNA precursor (SEQ ID NO. 162) ccugugcagagauuauuuuuuuuaaaaggucacaaucaacauucauugcugucgguggguugaacug uguggacaagcucacugaacaaugaaugcaacuguggcccgcuu hsa-miR-181b mature miRNA: (SEQ ID NO. 163) aacauucauugcugucgguggg hsa-mir-124a-3 pre-miRNA precursor: (SEQ ID NO.
  • the present invention also provides orthologues of the above human miRNAs, which may identified by method known in the art.
  • a database of miRNAs is found at the miRBase registry (http://microrna.sanger.ac.uk/sequences/).
  • the present invention specifically provides in its various forms the following microRNAs: hsa-let-7a-1, hsa-let-7a-2, hsa-let-7a-3, hsa-let-7b, hsa-let-7c, hsa-let-7f, hsa-miR-10b, hsa-miR-15a, hsa-miR-15b, hsa-miR-16, hsa-miR-19b mature miRNA, hsa-miR-20, hsa-miR-21, hsa-miR-22, hsa-miR-23a, hsa-miR-24, hsa-miR-189, hsa-miR-24, hsa-miR-26, hsa-miR-26b, hsa-miR-26a, hsa-miR-27b, hsa
  • miRNAs are small RNA molecules endogenously encoded in the genome of many species that regulate gene expression by binding to specific mRNAs. miRNAs are formed from larger transcripts that fold to produce hairpin structures and serve as substrates for the Dicer family of RNase III enzymes. The products of Dicer cleavage are short dsRNA molecules, one strand of which is retained in a ribonucleoprotein complex called the RNA-induced silencing complex (RISC). The retained RNA acts as a guide to direct this complex to a target site in the mRNA which is then inactivated either by cleavage or translational interference, depending on the degree of complementarity between the miRNA and its target site.
  • RISC RNA-induced silencing complex
  • the modulation of the development of a cell in the various forms of the present invention may be by way of cleavage (or lack of cleavage) of the nucleic acid with the capacity to modulate the development of the cell, and/or by way of translational interference (or lack of translational interference) of the nucleic acid with the capacity to modulate the development of the cell.
  • the target site in the various forms of the present invention may be a nucleotide sequence that has exact complementarity to the miRNA, or alternatively, be a target site with a reduced degree of complementarity.
  • Methods for determining the extent of complementarity required for binding of a miRNA are known in the art, for example Lewis B P, Burge CB, Bartel D P., (2005) conserveed seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.
  • the target site may be a natural target site or a non-naturally occurring target site.
  • the target site may be introduced into the nucleic acid with one or more addition nucleotides from the gene.
  • the target site may be introduced by way of using the entire 3′UTR of a gene having a suitable target site in that untranslated region of the mRNA.
  • a miRNA to bind to a target site and cleave the mRNA and/or interfere with translation may be confirmed experimentally by a suitable method known in the art.
  • a suitable method known in the art.
  • the psiCHECKTM2 Luciferase assay system Promega
  • Northern blot and RT-PCR analyses can also be used to determine cleavage of a target transcript, while Western blot analysis will detect reduced translation of encoded proteins.
  • complementary target sites for the binding of the miRNAs are as follows (5′ to 3′):
  • hsa-let-7 mature miRNA target site AACUAUACAACCUACUACCUCA (SEQ ID NO. 99)
  • hsa-let-7a mature miRNA target site AACUAUACAACCUACUACCUCA (SEQ ID NO. 100)
  • hsa-let-7a mature miRNA target site AACUAUACAACCUACUACCUCA
  • hsa-let-7b mature miRNA target site AACCACACAACCUACUACCUCA (SEQ ID NO. 102)
  • hsa-let-7c mature miRNA target site AACCAUACAACCUACUACCUCA (SEQ ID NO.
  • hsa-let-7f mature miRNA target site AACUAUACAAUCUACUACCUCA
  • hsa-let-7f mature miRNA target site AACUAUACAAUCUACUACCUCA
  • hsa-miR-10b mature miRNA target site ACAAAUUCGGUUCUACAGGGUA
  • hsa-miR-15b mature miRNA target site UGUAAACCAUGAUGUGCUGCUA
  • hsa-miR-16 mature miRNA target site CGCCAAUAUUUACGUGCUGCUA (SEQ ID NO.
  • hsa-miR-16 mature miRNA target site CGCCAAUAUUUACGUGCUGCUA (SEQ ID NO. 109)
  • hsa-miR-19b mature miRNA target site UCAGUUUUGCAUGGAUUUGCACA (SEQ ID NO. 110)
  • hsa-miR-19b mature miRNA target site UCAGUUUUGCAUGGAUUUGCACA (SEQ ID NO. 111)
  • hsa-miR-20 mature miRNA target site CUACCUGCACUAUAAGCACUUUA
  • hsa-miR-21 mature miRNA target site UCAACAUCAGUCUGAUAAGCUA (SEQ ID NO.
  • hsa-miR-22 mature miRNA target site ACAGUUCUUCAACUGGCAGCUU
  • hsa-miR-23a mature miRNA target site GGAAAUCCCUGGCAAUGUGAU
  • hsa-miR-24 mature miRNA target site CUGUUCCUGCUGAACUGAGCCA
  • hsa-miR-189 mature miRNA target site ACUGAUAUCAGCUCAGUAGGCAC
  • hsa-miR-24 mature miRNA target site CUGUUCCUGCUGAACUGAGCCA (SEQ ID NO.
  • hsa-miR-26 mature miRNA target site GCCUAUCCUGGAUUACUUGAAU
  • hsa-miR-26b mature miRNA target site AACCUAUCCUGAAUUACUUGAA
  • hsa-miR-26a mature miRNA target site GCCUAUCCUGGAUUACUUGAA
  • hsa-miR-27b mature miRNA target site GCAGAACUUAGCCACUGUGAA
  • hsa-miR-29a mature miRNA target site AACCGAUUUCAGAUGGUGCUA (SEQ ID NO.
  • hsa-miR-30a-3p mature miRNA target site GCUGCAAACAUCCGACUGAAAG (SEQ ID NO. 124) hsa-miR-30a-5p mature miRNA target site: CUUCCAGUCGAGGAUGUUUACA (SEQ ID NO. 125) hsa-miR-141 mature miRNA target site: CCAUCUUUACCAGACAGUGUUA (SEQ ID NO. 126) hsa-miR-142-5p mature miRNA target site: GUAGUGCUUUCUACUUUAUG (SEQ ID NO. 127) hsa-miR-142-3p mature miRNA: UCCAUAAAGUAGGAAACACUACA (SEQ ID NO.
  • hsa-miR-143 mature miRNA target site UGAGCUACAGUGCUUCAUCUCA (SEQ ID NO. 129)
  • hsa-miR-145 mature miRNA target site AAGGGAUUCCUGGGAAAACUGGAC (SEQ ID NO. 130)
  • hsa-miR-192 mature miRNA target site GGCUGUCAAUUCAUAGGUCAG (SEQ ID NO. 131)
  • hsa-miR-194 mature miRNA target site: UCCACAUGGAGUUGCUGUUACA SEQ ID NO. 132)
  • hsa-miR-194 mature miRNA target site UCCACAUGGAGUUGCUGUUACA (SEQ ID NO. 132)
  • hsa-miR-199b mature miRNA target site GAACAGAUAGUCUAAACACUGGG
  • hsa-miR-200b mature miRNA target site GUCAUCAUUACCAGGCAGUAUUA
  • hsa-miR-200c mature miRNA target site CCAUCAUUACCCGGCAGUAUUA
  • hsa-miR-320 mature miRNA target site UUCGCCCUCUCAACCCAGCUUUU (SEQ ID NO. 137)
  • hsa-miR-321 mature miRNA target site GAACCCACAAUCCCUGGCUUA (SEQ ID NO.
  • hsa-miR-30a-3p mature miRNA target site GCUGCAAACAUCCGACUGAAAG
  • hsa-miR-30a-5p mature miRNA target site CUUCCAGUCGAGGAUGUUUACA
  • hsa-miR-29b mature miRNA target site AACACUGAUUUCAAAUGGUGCUA
  • hsa-miR-125b mature miRNA target site UCACAAGUUAGGGUCUCAGGGA
  • hsa-miR-125a mature miRNA target site CACAGGUUAAAGGGUCUCAGGGA (SEQ ID NO.
  • hsa-miR-125b mature miRNA target site UCACAAGUUAGGGUCUCAGGGA
  • hsa-miR-15a mature miRNA target site CACAAACCAUUAUGUGCUGCUA
  • hsa-miR-126* mature miRNA target site CGCGUACCAAAAGUAAUAAUG
  • hsa-miR-126 mature miRNA target site GCAUUAUUACUCACGGUACGA
  • hsa-miR-188 mature miRNA target site ACCCUCCACCAUGCAAGGGAUG (SEQ ID NO.
  • hsa-miR-331 mature miRNA target site UUCUAGGAUAGGCCCAGGGGC (SEQ ID NO. 149) hsa-miR-155 mature miRNA target site: CCCCUAUCACGAUUAGCAUUAA (SEQ ID NO. 150) hsa-miR-375 mature miRNA target site: UCACGCGAGCCGAACGAACAAA (SEQ ID NO. 164) hsa-miR-181b mature miRNA target site: CCCACCGACAGCAAUGAAUGUU (SEQ ID NO. 165) hsa-miR-124a mature miRNA target site: UGGCAUUCACCGCGUGCCUUAA (SEQ ID NO. 170) hsa-miR-9 mature miRNA target site: UCAUACAGCUAGAUAACCAAAGA (SEQ ID NO. 171)
  • nucleic acid molecule being a DNA
  • U bases substituted for T bases
  • the target site for binding of a microRNA in the various forms of the present invention may be a non-naturally occurring binding site for the particular miRNA, or alternatively, may be a target site present in a naturally occurring gene or mRNA, such as a target site found in the 3′UTR of a gene.
  • naturally and non-naturally occurring targets for a microRNA may be identified as described in Krek et al. (2005) Nature Genetics 37(5): 495-500.
  • Table 1 provides a listing of human mRNAs predicted to contain target sites for hsa-miR-143, using the method as described in Krek et al. (2005) Nature Genetics 37(5): 495-500, using default parameters.
  • NM_007306 Homo sapiens breast cancer 1, early onset (BRCA1), transcript variant BRCA1-exon4, mRNA. 14 NM_144633 5.05 Homo sapiens potassium voltage-gated channel, subfamily H (eag-related), member 8 (KCNH8), mRNA. 15 NM_153649 4.98 Homo sapiens tropomyosin 3 (TPM3), mRNA. 16 NM_004798 4.78 Homo sapiens kinesin family member 3B (KIF3B), mRNA. 17 NM_021907 4.69 Homo sapiens dystrobrevin, beta (DTNB), transcript variant 1, mRNA.
  • BRCA1 early onset
  • KCNH8 Homo sapiens potassium voltage-gated channel, subfamily H (eag-related), member 8 (KCNH8), mRNA. 15 NM_153649 4.98 Homo sapiens tropomyosin 3 (TPM3), mRNA. 16 NM_0047
  • NM_006302 4.23 Homo sapiens glucosidase I (GCS1), mRNA.
  • NM_024915 4.17 Homo sapiens transcription factor CP2-like 3 (TFCP2L3), mRNA.
  • TFCP2L3 transcription factor 2-like 3
  • mRNA 35
  • NM_000168 4.13 Homo sapiens GLI-Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome) (GLI3), mRNA.
  • NM_014450 3.99 Homo sapiens SHP2-interacting transmembrane adaptor protein (SIT), mRNA.
  • NM_014346 3.95 Homo sapiens chromosome 22 open reading frame 4 (C22orf4), mRNA.
  • NM_000633 3.86 Homo sapiens B-cell CLL/lymphoma 2 (BCL2), nuclear gene encoding mitochondrial protein, transcript variant alpha, mRNA. 39 NM_002314 3.86 Homo sapiens LIM domain kinase 1 (LIMK1), transcript variant 1, mRNA. 40 NM_173478 3.84 Homo sapiens hypothetical protein FLJ40137 (FLJ40137), mRNA. 41 NM_030952 3.84 Homo sapiens likely ortholog of rat SNF1/AMP-activated protein kinase (SNARK), mRNA. 42 NM_018579 3.8 Homo sapiens mitochondrial solute carrier protein (MSCP), mRNA.
  • MSCP mitochondrial solute carrier protein
  • NM_004089 3.75 Homo sapiens delta sleep inducing peptide, immunoreactor (DSIPI), transcript variant 2, mRNA. 44 NM_198057 3.75 Homo sapiens delta sleep inducing peptide, immunoreactor (DSIPI), transcript variant 1, mRNA. 45 NM_002830 3.72 Homo sapiens protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) (PTPN4), mRNA. 46 NM_006206 3.68 Homo sapiens platelet-derived growth factor receptor, alpha polypeptide (PDGFRA), mRNA.
  • PDGFRA alpha polypeptide
  • TEL oncogene ETV6
  • NM_014922 3.64 Homo sapiens NACHT, leucine rich repeat and PYD (pyrin domain) containing 1 (NALP1), transcript variant 2, mRNA. 52 NM_018398 3.63 Homo sapiens calcium channel, voltage-dependent, alpha 2/delta 3 subunit (CACNA2D3), mRNA. 53 NM_147159 3.6 Homo sapiens opioid receptor, sigma 1 (OPRS1), transcript variant 4, mRNA. 54 NM_000920 3.6 Homo sapiens pyruvate carboxylase (PC), nuclear gene encoding mitochondrial protein, transcript variant A, mRNA.
  • PC Homo sapiens pyruvate carboxylase
  • NM_022172 Homo sapiens pyruvate carboxylase (PC), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA.
  • PC Homo sapiens pyruvate carboxylase
  • ANXA3 Homo sapiens annexin A3
  • mRNA mRNA.
  • PPEF2 EF hand calcium- binding domain 2
  • TMEM27 Homo sapiens transmembrane protein 27
  • mRNA 59
  • NM_015513 Homo sapiens cysteine-rich with EGF-like domains 1 (CRELD1), mRNA.
  • 78 NM_198262 3.15 Homo sapiens similar to splicing factor, arginine/serine-rich 4 (FLJ11021), transcript variant 3, mRNA. 79 NM_018036 3.15 Homo sapiens chromosome 14 open reading frame 103 (C14orf103), mRNA. 80 NM_003188 3.14 Homo sapiens mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant A, mRNA. 81 NM_145331 3.14 Homo sapiens mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant B, mRNA.
  • MAP3K7 mitogen-activated protein kinase kinase kinase 7
  • NM_001795 3.12 Homo sapiens cadherin 5, type 2, VE-cadherin (vascular epithelium) (CDH5), mRNA.
  • NM_024490 3.12 Homo sapiens ATPase, Class V, type 10A (ATP10A), mRNA.
  • ATP10A vascular epithelium
  • mRNA mRNA
  • NM_019102 3.08 Homo sapiens homeo box A5 (HOXA5), mRNA.
  • NM_007375 3.06
  • Homo sapiens TAR DNA binding protein TARDBP
  • mRNA 86 NM_006769 3.04 Homo sapiens LIM domain only 4 (LMO4), mRNA.
  • FTHFD Homo sapiens formyltetrahydrofolate dehydrogenase
  • transcript variant 2 mRNA.
  • 93 NM_001901 2.88
  • CTGF connective tissue growth factor
  • 94 NM_004637 2.87
  • RAB7 member RAS oncogene family (RAB7), mRNA.
  • 95 NM_000210 2.86
  • 96 NM_014939 2.85 Homo sapiens KIAA1012 (KIAA1012), mRNA.
  • 106 NM_005584 2.73 Homo sapiens mab-21-like 1 ( C. elegans ) (MAB21L1), mRNA. 107 NM_022051 2.72 Homo sapiens egl nine homolog 1 ( C. elegans ) (EGLN1), mRNA. 108 NM_006621 2.72 Homo sapiens S-adenosylhomocysteine hydrolase-like 1 (AHCYL1), mRNA. 109 NM_003077 2.72 Homo sapiens SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2 (SMARCD2), mRNA.
  • SMARCD2 S-adenosylhomocysteine hydrolase-like 1
  • 114 NM_032980 2.68 Homo sapiens dystrobrevin, alpha (DTNA), transcript variant 6, mRNA. 115 NM_016824 2.68 Homo sapiens adducin 3 (gamma) (ADD3), transcript variant 1, mRNA. 116 NM_000291 2.68 Homo sapiens phosphoglycerate kinase 1 (PGK1), mRNA. 117 NM_153184 2.67 Homo sapiens immunoglobulin superfamily, member 4D (IGSF4D), mRNA. 118 NM_004384 2.67 Homo sapiens casein kinase 1, gamma 3 (CSNK1G3), mRNA.
  • NM_022552 2.65 Homo sapiens DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A), transcript variant 3, mRNA. 120 NM_175629 2.65 Homo sapiens DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A), transcript variant 1, mRNA. 121 NM_153759 2.65 Homo sapiens DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A), transcript variant 2, mRNA. 122 NM_178835 2.62 Homo sapiens hypothetical protein LOC152485 (LOC152485), mRNA.
  • LOC152485 LOC152485
  • NM_001005745 2.49 Homo sapiens numb homolog ( Drosophila ) (NUMB), transcript variant 4, mRNA. 134 NM_001005744 2.49 Homo sapiens numb homolog ( Drosophila ) (NUMB), transcript variant 2, mRNA. 135 NM_001005743 2.49 Homo sapiens numb homolog ( Drosophila ) (NUMB), transcript variant 1, mRNA. 136 NM_004274 2.48 Homo sapiens A kinase (PRKA) anchor protein 6 (AKAP6), mRNA. 137 NM_003489 2.47 Homo sapiens nuclear receptor interacting protein 1 (NRIP1), mRNA.
  • PRKA Homo sapiens A kinase anchor protein 6
  • NM_001331 2.45 Homo sapiens catenin (cadherin-associated protein), delta 1 (CTNND1), mRNA. 144 NM_030571 2.43 Homo sapiens Nedd4 family interacting protein 1 (NDFIP1), mRNA. 145 NM_004059 2.41 Homo sapiens cysteine conjugate-beta lyase; cytoplasmic (glutamine transaminase K, kyneurenine aminotransferase) (CCBL1), mRNA. 146 NM_080670 2.41 Homo sapiens solute carrier family 35, member A4 (SLC35A4), mRNA.
  • SLC35A4 solute carrier family 35, member A4
  • RNA 157 NM_199078 2.28 Homo sapiens cyclin M3 (CNNM3), transcript variant 2, mRNA. 158 NM_014424 2.28 Homo sapiens heat shock 27 kDa protein family, member 7 (cardiovascular) (HSPB7), mRNA. 159 NM_000599 2.27 Homo sapiens insulin-like growth factor binding protein 5 (IGFBP5), mRNA. 160 NM_021212 2.25 Homo sapiens HCF-binding transcription factor Zhangfei (ZF), mRNA. 161 NM_005110 2.24 Homo sapiens glutamine-fructose-6-phosphate transaminase 2 (GFPT2), mRNA.
  • GFPT2 glutamine-fructose-6-phosphate transaminase 2
  • 162 NM_022780 2.24 Homo sapiens hypothetical protein FLJ13910 (FLJ13910), mRNA. 163 NM_014574 2.23 Homo sapiens striatin, calmodulin binding protein 3 (STRN3), mRNA. 164 NM_153020 2.21 Homo sapiens RNA binding motif protein 24 (RBM24), mRNA. 165 NM_032221 2.2 Homo sapiens chromodomain helicase DNA binding protein 6 (CHD6), mRNA. 166 NM_004080 2.19 Homo sapiens diacylglycerol kinase, beta 90 kDa (DGKB), transcript variant 1, mRNA.
  • fibroblast growth factor 1 acidic
  • FGF1 fibroblast growth factor 1
  • transcript variant 1 mRNA.
  • PTGS2 prostaglandin G/H synthase and cyclooxygenase
  • mRNA. 169 NM_003413
  • ZIC3 Homo sapiens Zic family member 3 heterotaxy 1 (odd-paired homolog, Drosophila ) (ZIC3), mRNA. 170 NM_199182 2.1 Homo sapiens hLAT1-3TM (IMAA), mRNA.
  • IMAA Homo sapiens hLAT1-3TM
  • MAP1B Homo sapiens microtubule-associated protein 1B
  • MAP1B transcript variant 2
  • PHTF2 putative homeodomain transcription factor 2
  • ELMOD1 Homo sapiens ELMO domain containing 1
  • NM_004529 2 Homo sapiens myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila ); translocated to, 3 (MLLT3), mRNA.
  • MLLT3 Homo sapiens myeloid/lymphoid or mixed-lineage leukemia
  • 181 NM_032385 2 Homo sapiens chromosome 5 open reading frame 4 (C5orf4), mRNA.
  • 182 NM_002310 1.99 Homo sapiens leukemia inhibitory factor receptor (LIFR), mRNA.
  • 183 NM_000393 1.99 Homo sapiens collagen, type V, alpha 2 (COL5A2), mRNA.
  • NM_006489 1.86 Homo sapiens neuro-oncological ventral antigen 1 (NOVA1), transcript variant 2, mRNA. 190 NM_019087 1.86 Homo sapiens ADP-ribosylation factor related protein 2 (ARFRP2), mRNA. 191 NM_002515 1.86 Homo sapiens neuro-oncological ventral antigen 1 (NOVA1), transcript variant 1, mRNA. 192 NM_015200 1.81 Homo sapiens SCC-112 protein (SCC-112), mRNA.
  • SCC-112 protein SCC-112 protein
  • 202 NM_000868 1.63 Homo sapiens 5-hydroxytryptamine (serotonin) receptor 2C (HTR2C), mRNA.
  • 203 NM_014810 1.63 Homo sapiens centrosome-associated protein 350 (CAP350), mRNA.
  • CAP350 homosomal protein
  • mRNA mRNA
  • 204 NM_000721 1.61 Homo sapiens calcium channel, voltage-dependent, alpha 1E subunit (CACNA1E), mRNA.
  • 205 NM_002076 1.6 Homo sapiens glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) (GNS), mRNA.
  • cytoplasmic polyadenylation element binding protein 2 CPEB2
  • transcript variant A mRNA
  • CPEB2 cytoplasmic polyadenylation element binding protein 2
  • transcript variant B mRNA
  • NM_021079 1.55 Homo sapiens N-myristoyltransferase 1 (NMT1), mRNA. 209 NM_199324 1.47 Homo sapiens HIV-1 induced protein HIN-1 (HSHIN1), transcript variant 1, mRNA. 210 NM_145808 1.44 Homo sapiens myotrophin (MTPN), mRNA.
  • NMT1 N-myristoyltransferase 1
  • HSHIN1 HIV-1 induced protein HIN-1
  • MTPN Homo sapiens myotrophin
  • NM_005400 1.43 Homo sapiens protein kinase C, epsilon (PRKCE), mRNA.
  • 212 NM_181897 1.42 Homo sapiens protein phosphatase 2 (formerly 2A), regulatory subunit B′′, alpha (PPP2R3A), transcript variant 2, mRNA.
  • 213 NM_002718 1.42 Homo sapiens protein phosphatase 2 (formerly 2A), regulatory subunit B′′, alpha (PPP2R3A), transcript variant 1, mRNA.
  • 214 NM_001438 1.2 Homo sapiens estrogen-related receptor gamma (ESRRG), transcript variant 1, mRNA.
  • ESRRG estrogen-related receptor gamma
  • ESRRG Homo sapiens estrogen-related receptor gamma
  • transcript variant 215 NM_206594 1.2 Homo sapiens estrogen-related receptor gamma (ESRRG), transcript variant 2, mRNA.
  • 216 NM_206595 1.2 Homo sapiens estrogen-related receptor gamma (ESRRG), transcript variant 3, mRNA.
  • Table 2 provides a listing of human mRNAs predicted to contain target sites for hsa-miR-145, using the method as described in Krek et al. (2005) Nature Genetics 37(5): 495-500, using default parameters.
  • NM_005797 7.62 Homo sapiens epithelial V-like antigen 1 (EVA1), transcript variant 1, mRNA. 7 NM_014871 7.58 Homo sapiens ubiquitin specific protease 52 (USP52), mRNA. 8 NM_001128 7.54 Homo sapiens adaptor-related protein complex 1 gamma 1 subunit (AP1G1), mRNA. 9 NM_015271 7.44 Homo sapiens tripartite motif-containing 2 (TRIM2), mRNA. 10 NM_017999 7.08 Homo sapiens ring finger protein 31 (RNF31), mRNA.
  • NM_005347 Homo sapiens heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5), mRNA. 26 NM_015184 5.21 Homo sapiens phospholipase C-like 2 (PLCL2), mRNA. 27 NM_052830 5.18 Homo sapiens gamma-glutamyltransferase-like 3 (GGTL3), transcript variant 1, mRNA. 28 NM_002657 5.13 Homo sapiens pleiomorphic adenoma gene-like 2 (PLAGL2), mRNA.
  • NM_033274 Homo sapiens a disintegrin and metalloproteinase domain 19 (meltrin beta) (ADAM19), transcript variant 2, mRNA.
  • ADAM19 disintegrin and metalloproteinase domain 19
  • transcript variant 2 mRNA.
  • C14orf140 Homo sapiens chromosome 14 open reading frame 140
  • NM_017913 Homo sapiens cell division cycle 37 homolog ( S. cerevisiae )-like 1 (CDC37L1), mRNA.
  • NM_005384 4.42 Homo sapiens nuclear factor, interleukin 3 regulated (NFIL3), mRNA.
  • NFIL3 interleukin 3 regulated
  • GGTL3 gamma-glutamyltransferase-like 3
  • transcript variant 3 mRNA.
  • GGTL3 gamma-glutamyltransferase-like 3
  • GGTL3 gamma-glutamyltransferase-like 3
  • GGTL3 gamma-glutamyltransferase-like 3
  • GGTL3 gamma-glutamyltransferase-like 3
  • CXorf15 chromosome X open reading frame 15
  • mRNA 43
  • NM_016032 4.29 Homo sapiens zinc finger, DHHC domain containing 9 (ZDHHC9), mRNA.
  • ZDHHC9 DHHC domain containing 9
  • mRNA 44
  • NM_016258
  • NM_182664 4.23 Homo sapiens Ras association (RalGDS/AF-6) domain family 5 (RASSF5), transcript variant 2, mRNA.
  • RASSF5 Ras association domain family 5
  • transcript variant 2 mRNA.
  • NM_006702 4.22 Homo sapiens neuropathy target esterase (NTE), mRNA.
  • NM_006080 4.2 Homo sapiens sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A (SEMA3A), mRNA.
  • NM_004276 4.12 Homo sapiens calcium binding protein 1 (calbrain) (CABP1), transcript variant 2, mRNA.
  • NM_031205 4.12 Homo sapiens calcium binding protein 1 (calbrain) (CABP1), transcript variant 1, mRNA. 50 NM_147193 4.05 Homo sapiens GLIS family zinc finger 1 (GLIS1), mRNA. 51 NM_004865 4.02 Homo sapiens TBP-like 1 (TBPL1), mRNA. 52 NM_001284 4.02 Homo sapiens adaptor-related protein complex 3, sigma 1 subunit (AP3S1), transcript variant 1, mRNA. 53 NM_022652 3.98 Homo sapiens dual specificity phosphatase 6 (DUSP6), transcript variant 2, mRNA.
  • GLIS1 GLIS family zinc finger 1
  • TBPL1 TBP-like 1
  • A3S1 Homo sapiens adaptor-related protein complex 3 sigma 1 subunit
  • DUSP6 dual specificity phosphatase 6
  • TIR toll-interleukin 1 receptor
  • 73 NM_184042 3.63 Homo sapiens Cohen syndrome 1 (COH1), transcript variant 2, mRNA.
  • 74 NM_001457 3.63 Homo sapiens filamin B, beta (actin binding protein 278) (FLNB), mRNA.
  • 75 NM_032511 3.56 Homo sapiens chromosome 6 open reading frame 168 (C6orf168), mRNA.
  • 77 NM_001326 3.54 Homo sapiens cleavage stimulation factor, 3′ pre-RNA, subunit 3, 77 kDa (CSTF3), mRNA.
  • SACM1L Homo sapiens SAC1 suppressor of actin mutations 1-like (yeast)
  • LRC leukocyte receptor cluster
  • EFO1 Homo sapiens establishment factor-like protein
  • SEPT6 Homo sapiens septin 6
  • NM_002924 3.43 Homo sapiens regulator of G-protein signalling 7 (RGS7), mRNA.
  • NM_002229 3.42 Homo sapiens jun B proto-oncogene (JUNB), mRNA.
  • CAMK1D Homo sapiens calcium/calmodulin-dependent protein kinase ID
  • transcript variant 2 mRNA.
  • CAMK1D calcium/calmodulin-dependent protein kinase ID
  • TRRAP3 Homo sapiens thyroid hormone receptor associated protein 3
  • mRNA 87 NM_173078 3.34 Homo sapiens SLIT and NTRK-like family, member 4 (SLITRK4), mRNA.
  • 88 NM_003893 3.31 Homo sapiens LIM domain binding 1 (LDB1), mRNA.
  • 91 NM_133370 3.24 Homo sapiens splicing factor YT521-B (YT521), mRNA.
  • 92 NM_015069 3.23 Homo sapiens zinc finger protein 423 (ZNF423), mRNA.
  • UXS1 UDP-glucuronate decarboxylase 1
  • DRB1 developmentally regulated RNA- binding protein 1
  • SMAP small acidic protein
  • ZNF236 Homo sapiens zinc finger protein 236
  • ZNF236 zinc finger protein 236
  • ribosomal protein S6 kinase 90 kDa, polypeptide 5 (RPS6KA5), transcript variant 1, mRNA.
  • 108 NM_001901 2.99 Homo sapiens connective tissue growth factor (CTGF), mRNA. 109 NM_018270 2.98 Homo sapiens chromosome 20 open reading frame 20 (C20orf20), mRNA.
  • 110 NM_001092 2.98 Homo sapiens active BCR-related gene (ABR), transcript variant 2, mRNA. 111 NM_021962 2.98 Homo sapiens active BCR-related gene (ABR), transcript variant 1, mRNA.
  • NM_182527 2.97 Homo sapiens calcium binding protein 7 (CABP7), mRNA. 113 NM_021612 2.96 Homo sapiens a disintegrin and metalloproteinase domain 11 (ADAM11), transcript variant 2, mRNA. 114 NM_020806 2.96 Homo sapiens gephyrin (GPHN), mRNA. 115 NM_000959 2.95 Homo sapiens prostaglandin F receptor (FP) (PTGFR), mRNA. 116 NM_016322 2.94 Homo sapiens RAB14, member RAS oncogene family (RAB14), mRNA.
  • CABP7 calcium binding protein 7
  • ADAM11 disintegrin and metalloproteinase domain 11
  • ADAM11 disintegrin and metalloproteinase domain 11
  • mRNA 114 NM_020806
  • GPHN disintegrin and metalloproteinase domain 11
  • GPHN disintegrin and metall
  • NM_015277 2.8 Homo sapiens neural precursor cell expressed, developmentally down-regulated 4-like (NEDD4L), mRNA. 131 NM_017732 2.8 Homo sapiens hypoxia-inducible factor prolyl 4- hydroxylase (PH-4), transcript variant 2, mRNA. 132 NM_133476 2.79 Homo sapiens zinc finger protein 384 (ZNF384), mRNA. 133 NM_022845 2.79 Homo sapiens core-binding factor, beta subunit (CBFB), transcript variant 1, mRNA. 134 NM_207424 2.77 Homo sapiens FLJ40536 protein (FLJ40536), mRNA.
  • NEDD4L developmentally down-regulated 4-like
  • PH-4 Homo sapiens hypoxia-inducible factor prolyl 4- hydroxylase
  • ZNF384 zinc finger protein 384
  • CBFB beta subunit
  • FLJ40536 protein FLJ40536
  • acyl-CoA synthetase long-chain family member 4 (ACSL4), transcript variant 1, mRNA.
  • 140 NM_022832 2.73 Homo sapiens ubiquitin specific protease 46 (USP46), mRNA.
  • 141 NM_025057 2.73 Homo sapiens chromosome 14 open reading frame 45 (C14orf45), mRNA.
  • 142 NM_130436 2.72 Homo sapiens dual-specificity tyrosine-(Y)- phosphorylation regulated kinase 1A (DYRK1A), transcript variant 2, mRNA.
  • Homo sapiens likely ortholog of mouse roof plate-specific spondin (R-spondin), mRNA. 153 NM_014212 2.67 Homo sapiens homeo box C11 (HOXC11), mRNA. 154 NM_001259 2.67 Homo sapiens cyclin-dependent kinase 6 (CDK6), mRNA. 155 NM_005721 2.64 Homo sapiens ARP3 actin-related protein 3 homolog (yeast) (ACTR3), mRNA. 156 NM_014603 2.64 Homo sapiens paraneoplastic antigen (HUMPPA), mRNA.
  • MAPK1 mitogen-activated protein kinase 1
  • FMNL2 Homo sapiens formin-like 2
  • 166 NM_006922 2.52 Homo sapiens sodium channel, voltage-gated, type III, alpha (SCN3A), mRNA. 167 NM_032017 2.52 Homo sapiens Ser/Thr-like kinase (MGC4796), mRNA. 168 NM_024595 2.51 Homo sapiens hypothetical protein FLJ12666 (FLJ12666), mRNA. 169 NM_004393 2.5 Homo sapiens dystroglycan 1 (dystrophin- associated glycoprotein 1) (DAG1), mRNA. 170 NM_198793 2.48 Homo sapiens CD47 antigen (Rh-related antigen, integrin-associated signal transducer) (CD47), transcript variant 2, mRNA.
  • DAG1 Homo sapiens CD47 antigen
  • CD47 transcript variant 2 mRNA.
  • NM_002142 Homo sapiens homeo box A9 (HOXA9), transcript variant 2, mRNA.
  • 202 NM_017772 2.22 Homo sapiens chromosome 6 open reading frame 197 (C6orf197), mRNA.
  • 203 NM_017582 2.22 Homo sapiens ubiquitin-conjugating enzyme E2Q (putative) (UBE2Q), mRNA.
  • 204 NM_006469 2.22 Homo sapiens influenza virus NS1A binding protein (IVNS1ABP), transcript variant 1, mRNA.
  • 205 NM_002840 2.19 Homo sapiens protein tyrosine phosphatase, receptor type, F (PTPRF), transcript variant 1, mRNA.
  • PPRF Homo sapiens protein tyrosine phosphatase, receptor type, F (PTPRF), transcript variant 1, mRNA.
  • 206 NM_130440 2.19 Homo sapiens protein tyrosine phosphatase, receptor type, F (PTPRF), transcript variant 2, mRNA. 207 NM_199437 2.17 Homo sapiens PR domain containing 10 (PRDM10), transcript variant 2, mRNA. 208 NM_199439 2.17 Homo sapiens PR domain containing 10 (PRDM10), transcript variant 4, mRNA. 209 NM_199438 2.17 Homo sapiens PR domain containing 10 (PRDM10), transcript variant 3, mRNA. 210 NM_005604 2.17 Homo sapiens POU domain, class 3, transcription factor 2 (POU3F2), mRNA.
  • POU3F2 transcription factor 2
  • Homo sapiens inhibin, beta B (activin AB beta polypeptide) (INHBB), mRNA. 217 NM_207438 2.12 Homo sapiens FLJ43808 protein (FLJ43808), mRNA. 218 NM_020689 2.12 Homo sapiens solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 (SLC24A3), mRNA. 219 NM_012271 2.1 Homo sapiens huntingtin interacting protein B (HYPB), transcript variant 2, mRNA. 220 NM_023079 2.09 Homo sapiens hypothetical protein FLJ13855 (FLJ13855), mRNA.
  • beta B activin AB beta polypeptide
  • NM_003204 2.03 Homo sapiens nuclear factor (erythroid-derived 2)-like 1 (NFE2L1), mRNA. 228 NM_006459 2.02 Homo sapiens SPFH domain family, member 1 (SPFH1), mRNA. 229 NM_006403 1.99 Homo sapiens neural precursor cell expressed, developmentally down-regulated 9 (NEDD9), mRNA. 230 NM_003483 1.93 Homo sapiens high mobility group AT-hook 2 (HMGA2), mRNA. 231 NM_203351 1.92 Homo sapiens mitogen-activated protein kinase kinase kinase 3 (MAP3K3), transcript variant 1, mRNA.
  • HMGA2 high mobility group AT-hook 2
  • MAP3K3 mitogen-activated protein kinase kinase kinase 3
  • NM_002401 Homo sapiens mitogen-activated protein kinase kinase kinase 3 (MAP3K3), transcript variant 2, mRNA. 233 NM_003887 1.92 Homo sapiens development and differentiation enhancing factor 2 (DDEF2), mRNA. 234 NM_013449 1.85 Homo sapiens bromodomain adjacent to zinc finger domain, 2A (BAZ2A), mRNA. 235 NM_003507 1.84 Homo sapiens frizzled homolog 7 ( Drosophila ) (FZD7), mRNA. 236 NM_014686 1.81 Homo sapiens KIAA0355 (KIAA0355), mRNA.
  • MA3K3 mitogen-activated protein kinase kinase kinase 3
  • DDEF2 Homo sapiens development and differentiation enhancing factor 2
  • BAZ2A Homo sapiens bromodomain adjacent to zinc finger domain
  • BAZ2A
  • BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) (BMPR2), transcript variant 1, mRNA. 251 NM_004921 1.48 Homo sapiens chloride channel, calcium activated, family member 3 (CLCA3), mRNA. 252 NM_005502 1.47 Homo sapiens ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1), mRNA. 253 NM_148171 1.4 Homo sapiens ubiquitin associated protein 2 (UBAP2), transcript variant 3, mRNA.
  • BC1 sub-family A
  • ABCA1 member 1
  • UBAP2 Homo sapiens ubiquitin associated protein 2
  • NM_015071 1.38 Homo sapiens Rho GTPase activating protein 26 (ARHGAP26), mRNA. 255 NM_030627 1.34 Homo sapiens cytoplasmic polyadenylation element binding protein 4 (CPEB4), mRNA. 256 NM_030918 1.19 Homo sapiens sorting nexin family member 27 (SNX27), mRNA. 257 NM_004171 1.11 Homo sapiens solute carrier family 1 (glial high affinity glutamate transporter), member 2 (SLC1A2), mRNA. 258 NM_021813 0.97 Homo sapiens BTB and CNC homology 1, basic leucine zipper transcription factor 2 (BACH2), mRNA.
  • BACH2 basic leucine zipper transcription factor 2
  • a target site for the binding of the microRNA may be introduced into the nucleic acid with the capacity to modulate the development of cell at a suitable position in the nucleic acid.
  • the target site(s) may be introduced into one or more of the 3′UTR, coding region and 5′UTR of the mRNA.
  • the target site for the miR-143 and/or miR-145 microRNAs may be cloned into the 3′UTR of the HSV thymidine kinase gene.
  • This construct when expressed in cells with a reduced activity and/or expression of the miR-143 or miR-145 microRNAs, will lead to selective ablation of these cells.
  • the target site for introduction into the nucleic acid may be produced by a method known in the art, such as chemical synthesis.
  • phosphorothioate oligonucleotides may be synthesized by the method as described in Stein et al. (1988) Nucl. Acids Res. 16: 3209.
  • the target site may then be introduced into the nucleic acid by a method known in the art.
  • complementary oligonucleotides containing the binding site may be annealed and then introduced into the appropriate restriction site in a plasmid.
  • the nucleic acid with the capacity to modulate development of a cell may include more than one copy of a target site for binding of the miRNA.
  • the nucleic acid may contain 2, 3, 4 or more copies of a target site. Indeed, it is anticipated that multiple copies of a target site may provide a greater degree of control of the level of expression of the nucleic acid with the capacity to modulate development of the cell.
  • the copies of the target site may be copies of the same or a similar target sequence, or one or more copies of a target sequence for one or more different microRNA(s).
  • the present invention also provides a cell including an exogenous nucleic acid including a binding site for a microRNA, or a cell including a nucleic acid with a non-naturally occurring binding site for a microRNA.
  • the cell is a cancerous or pre-cancerous cell with a reduced activity of a microRNA.
  • cancerous and pre-cancerous cells are as previously discussed herein.
  • the present invention provides a cancerous or pre-cancerous cell including an exogenous nucleic acid including a binding site for a microRNA, wherein the cancerous or pre-cancerous cell has a reduced activity and/or concentration of the microRNA as compared to a similar non-cancerous cell.
  • the cell such as a pre-cancerous or cancerous cell, may be present in vitro or in vivo.
  • the cell may be an isolated cell in vitro, or a cell present in a biological system such as an organ, tissue, or an entire organism (eg an animal or human subject).
  • the present invention also provides an animal or human including non-cancerous cells and cancerous cells, the non-cancerous and cancerous cells both including and/or expressing an exogenous nucleic acid with a target site for binding of a microRNA.
  • the present invention provides an animal including cancerous cells, the cancerous cells including an exogenous nucleic acid including a target site for binding of a microRNA.
  • the target site for binding of a microRNA is a target site for a microRNA that has reduced expression and/or activity in the cancerous cell, as compared to a similar non-cancerous cell.
  • binding sites are as previously herein discussed and include the binding site for the miR-143 and/or miR-145 microRNAs.
  • the exogenous nucleic acid has the capacity to modulate the development of a cell in the animal.
  • examples of such nucleic acids are as previously discussed herein.
  • an exogenous nucleic acid in a cell may be by way of introducing the nucleic acid into the cells by a method known in the art. Methods for introducing exogenous DNAs into prokaryotic and eukaryotic cells are essentially as described in Sambrook, J, Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual 2nd. ed. Cold Spring Harbor Laboratory Press, New York. (1989).
  • the animal may also be a transgenic animal with the nucleic acid stably integrated into the genome of the cells of the animal.
  • Methods for producing transgenic animals are known in the art.
  • the present invention also provides a nucleic acid that has the capacity to modulate development of a cell and which includes a binding site for a microRNA.
  • Nucleic acids in the various forms of the present invention may be produced by a method known in the art, such as cloning, in vitro transcription (for a RNA), chemical synthesis or any combination of such methods.
  • the present invention also provides vectors including the nucleic acids of the present invention, and cells including the vectors and nucleic acids.
  • nucleic acids with the capacity to modulate the development of cells are as previously discussed herein.
  • the nucleic acid may have the capacity to inhibit the development of a cell (eg cytostatic or cytotoxic activity), or alternatively, may have the capacity to promote development of a cell.
  • the present invention provides a nucleic acid with the capacity to modulate development of a cell, the nucleic acid including a binding site for a microRNA.
  • the nucleic acid including a binding site for a microRNA. Examples of binding sites for microRNAs are as previously discussed herein.
  • the binding site for the microRNA is a binding site for a microRNA that has an altered activity and/or concentration in a cell, as compared to another cell.
  • the nucleic acid may include a binding for a microRNA that is differentially expressed and/or differentially active.
  • the nucleic acid may have the capacity to either inhibit or promote development of a cell.
  • Examples of nucleic acids that have the capacity to modulate development are as discussed previously herein.
  • nucleic acids of the present invention may be used in a composition for exposure to a cell, so as to introduce the nucleic acid into the cell, or a composition for administration to an animal or human subject, or be part of a vector, such as a viral vector, for introducing the nucleic acids into cells in vitro, or cells in a biological system, such as cells in an animal or human subject.
  • a vector such as a viral vector
  • the nucleic acid may be used for example to inhibit the development of a cell(s) in an animal or human subject, such as ablating the cell(s) in an animal or human subject.
  • the nucleic acid in the various forms of the present invention may be an isolated nucleic acid.
  • isolated is to be understood to mean an entity, for example a nucleic acid, a polypeptide, or a cell, which is removed from its natural environment.
  • the nucleic acid in the various forms of the present invention may also be present and/or expressed in a cell.
  • the present invention also provides a cell including an exogenous nucleic with the capacity to modulate development of the cell, the nucleic acid including a binding site for a microRNA.
  • the cell may be a prokaryotic cell or a eukaryotic cell.
  • An example of a suitable prokaryotic cell is Escherichia coli . Such a cell is useful for maintaining and/or propagating plasmids including the nucleic acid.
  • An example of a suitable eukaryotic cell is a human colon cell, or cell derived therefrom.
  • the cell is a eukaryotic cell that has an altered level and/or activity of one or more microRNAs. Examples of such cells are as previously discussed herein.
  • the cell may be an isolated cell in vitro, or a cell present in a biological system such as an organ, tissue, or an entire organism (eg an animal or human subject).
  • the cell is a cancerous or pre-cancerous cell with a reduced activity of a microRNA.
  • the present invention provides a cancerous or pre-cancerous cell with reduced activity of a microRNA, the cancerous or pre-cancerous cell including an exogenous nucleic with the capacity to modulate development of the cell, the nucleic acid including a binding site for the microRNA.
  • the reduced activity of the microRNA is as compared to a similar non-cancerous cell.
  • the cancerous or pre-cancerous cell may be an isolated cell in vitro, or a cell present in a biological system such as an organ, tissue, or an entire organism (eg an animal or human subject).
  • the cells may be present in a whole animal or human that contains non-cancerous cells and cancerous cells, both of which express an exogenous nucleic with the capacity to modulate development of the cell, the nucleic acid including a binding site for a microRNA.
  • the present invention also provides an animal including non-cancerous cells and cancerous cells, the non-cancerous and cancerous cells both including and/or expressing an exogenous nucleic acid with the capacity to modulate development of the cell, the nucleic acid including a binding site for a microRNA.
  • the binding site for the microRNA is a binding site for a microRNA that has an altered activity and/or concentration in the cancerous cells as compared to the non-cancerous cells.
  • the present invention also provides a nucleic acid including a non-naturally occurring binding site for a microRNA that is differentially expressed and/or has differential activity.
  • the present invention provides a nucleic acid including a non-naturally occurring binding site for a microRNA, wherein the microRNA is differentially expressed or differentially active between cells.
  • the nucleic acid may be an isolated nucleic acid.
  • the nucleic acid may be present and/or expressed in a cell.
  • the binding site for the differentially expressed or active microRNA is a binding site of a microRNA that has altered expression and/or activity between different types of cells.
  • the cells are of a similar type.
  • differentially expressed microRNAs include the miR-143 and miR-145 microRNAs, which are differentially expressed between colonic tumours and normal colonic tissue.
  • the binding site is a non-naturally occurring binding site for a microRNA that has an altered expression and/or activity in cancerous or pre-cancerous cells, as compared to the level of expression and/or activity in normal or non-cancerous cells.
  • the microRNA may have a reduced expression and/or activity in cancerous or pre-cancerous cells, as compared to the level of expression and/or activity in normal or non-cancerous cells.
  • the present invention provides an isolated nucleic acid including a non-naturally occurring binding site for a microRNA that is down-regulated in a cancerous cell as compared to a similar non-cancerous cell.
  • the nucleic acid is a nucleic acid with the capacity to modulate development of a cell.
  • Nucleic acids that have the capacity to modulate the development of a cell are as previously discussed herein.
  • the nucleic acid may inhibit (eg have cytotoxic or cytostatic activity) or promote the development of a cell.
  • the nucleic acid includes two or more binding sites for binding of the same or different microRNAs that are differentially expressed and/or differentially active.
  • the nucleic acid may be used in a composition for exposure to a cell, so as to introduce the nucleic acid into the cell, or for administration to an animal or human subject, or be part of a vector, such as a viral vector, for introducing into cells, including cells in an animal or human subject.
  • a vector such as a viral vector
  • the nucleic acid is used to inhibit the development of a cell(s) in an animal or human subject, including the ablation of the cell(s) in an animal or human subject.
  • the BLAST algorithm can be used for determining the extent of nucleotide homology between a target sequence and sequences in a specific genome.
  • BLAST identifies local alignments between the sequences in the database and predicts the probability of the local alignment occurring by chance.
  • the BLAST algorithm is as described in Altschul et al. (1990) J. Mol. Biol. 215:403-410.
  • the nucleic acid may be an exogenous nucleic acid introduced into a cell and then expressed.
  • the present invention also provides a cell including a nucleic acid including a non-naturally occurring binding site for a microRNA that is differentially expressed and/or differentially active.
  • the cell may be a prokaryotic cell or a eukaryotic cell.
  • An example of a suitable prokaryotic cell is Escherichia coli . Such a cell is useful for maintaining and/or propagating plasmids including the nucleic acid.
  • the cell is a eukaryotic cell that has an altered level and/or activity of one or more microRNAs. Examples of such cells are as previously described herein.
  • the cell may be an isolated cell in vitro, or a cell present in a biological system such as cell present in an organ, tissue, or an entire organism (eg an animal or human subject).
  • the cell is a cancerous or pre-cancerous cell.
  • the present invention provides a cancerous or pre-cancerous cell including a nucleic acid including a non-naturally occurring binding site for a microRNA.
  • the cell is a cancerous or pre-cancerous cell with a reduced activity of a microRNA.
  • the present invention provides a cancerous or pre-cancerous cell with reduced activity of a microRNA, the cancerous or pre-cancerous cell including a nucleic acid including a non-naturally occurring binding site for a microRNA that is differentially expressed and/or differentially active in the cancerous or pre-cancerous cell as compared to a similar non-cancerous cell.
  • the cells may be present in a whole animal or human that contains non-cancerous cells and cancerous cells, either or both of which include and/or express a nucleic acid including a non-naturally occurring binding site for a microRNA.
  • the present invention provides an animal including cancerous cells, the cancerous cells including a nucleic acid including a non-naturally occurring binding site for a microRNA.
  • the microRNA is differentially expressed or differentially active in the cancerous cells as compared to non-cancerous cells.
  • the present invention provides an animal including non-cancerous cells and cancerous cells, the non-cancerous and cancerous cells both including and/or expressing a nucleic acid including a non-naturally occurring binding site for a microRNA that is differentially expressed or differentially active in the cancerous cell as compared to the non-cancerous cell.
  • the nucleic acids of the present invention may be introduced into a cell by a suitable method known in art.
  • the nucleic acid may be introduced into a cell by transformation using calcium phosphate, viral infection, electroporation, lipofection, or particle bombardment.
  • transformed cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, or cells which transiently express the inserted DNA or RNA for limited periods of time.
  • Methods for introducing exogenous DNAs into prokaryotic and eukaryotic cells are essentially as described in Sambrook, J, Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual 2nd. ed. Cold Spring Harbor Laboratory Press, New York. (1989).
  • the mRNA may be produced in the cell by transcription of the relevant DNA.
  • the mRNA may be an exogenous mRNA introduced into the cell. Methods for producing mRNAs in vitro are known in the art.
  • the target site may be cloned into a suitable expression vector for use in the cell type of interest by methods known in the art. Methods for the isolation of nucleic acid sequences and their cloning into a suitable expression vector are essentially as described in Sambrook, J, Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual 2nd. ed. Cold Spring Harbor Laboratroy Press, New York. (1989). The recombinant molecule may then be introduced into the cell and the cloned nucleic acid expressed.
  • the vector may be any nucleic acid capable of having a foreign nucleic acid inserted into the vector.
  • the vector may be a plasmid, all or part of a viral genome, or any other nucleic acid capable of autonomous replication in a prokaryotic or eukaryotic host.
  • the present invention also provides a vector including the various nucleic acids of the present invention.
  • the vector is a viral vector that allows the nucleic acid to be introduced into the target cells by infection.
  • viral vectors that can be employed to deliver the nucleic acid to a cell include a recombinant adenovirus, a recombinant lentivirus, a recombinant retrovirus, a recombinant adeno-associated virus (AAV), a recombinant herpesvirus, a recombinant SV-40 virus, an Epstein-Barr virus, or a recombinant pox virus, such as a recombinant vaccinia virus.
  • the present invention provides a viral vector including a nucleic acid with the capacity to modulate development of a cell, the nucleic acid including a binding site for a microRNA.
  • the present invention also provides a viral vector including a nucleic acid including a non-naturally occurring binding site for a differentially expressed microRNA.
  • the viral vector may be formed from all or part of a viral genome.
  • the viral vector may also be a naturally occurring or a recombinant virus and further may be replication deficient or replication proficient.
  • expression of the relevant inserted DNA in plasmid or viral vectors will generally require various regulatory elements known in the art for the expression of inserted nucleic acids, for example promoters for driving the expression of an inserted nucleic acid in a particular cell, poly A signals for efficient polyadenylation of mRNA transcribed from inserted nucleic acids, or other regulatory elements to control translation, transcription or mRNA stability.
  • the promoter driving the expression may be a constitutive promoter, an inducible promoter or a cell or tissue specific promoter.
  • Constitutive mammalian promoters include hypoxanthine phosphoribosyl transferase (HPTR), adenosine deaminase, phosphoglycerate kinase, pyruvate kinase, and ⁇ -actin.
  • Exemplary viral promoters which function constitutively in eukaryotic cells include promoters from the simian virus, papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of moloney leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus.
  • Inducible promoters include synthetic promoters regulated by the TetO/TetR system and inducible promoters such as metallothionein promoter, which may be used to induced transcription in the presence of certain metal ions. Other inducible promoters are known in the art.
  • tissue-specific promoter will depend upon the particular cell type.
  • promoters that allow expression in colon cancer cells include the regulatory sequences of human carcinoembryonic antigen (CEA) [accession:U17131; gi/967132].
  • the present invention also provides a composition including the various nucleic acids described herein.
  • the present invention also provides a composition including a nucleic acid with the capacity to modulate development of a cell, the nucleic acid including a binding site for a microRNA.
  • the present provides a composition including a nucleic acid including a non-naturally occurring binding site for a differentially expressed or differentially active microRNA.
  • compositions are suitable for exposing the nucleic acids of the present invention to cells.
  • Methods of introducing nucleic acids into cells are as previously discussed herein.
  • compositions of the present invention are also suitable for administration to a subject to prevent and/or treat a disease, condition or state associated with cells that have an altered activity and/or expression of a microRNA.
  • the nucleic acids may be combined with a pharmaceutically acceptable carrier, stabilizer, buffer or diluent to produce a composition for administration to a subject.
  • a pharmaceutical composition including one or more nucleic acids of the invention in an acceptable carrier.
  • the nucleic acid may be delivered to a cell or a subject by a method known in the art.
  • the nucleic acid molecules can be administered to cells by encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as biodegradable polymers, hydrogels, cyclodextrins, poly(lactic-co-glycolic)acid (PLGA) and PLCA microspheres, biodegradable nanocapsules, and bioadhesive microspheres.
  • the nucleic acid molecules may also be formulated or complexed with polyethyleneimine and derivatives thereof, such as polyethyleneimine-polyethyleneglycol-N-acetylgalactosamine (PEI-PEG-GAL) or polyethyleneimine-polyethyleneglycol-tri-N-acetylgalac-tosamine (PEI-PEG-triGAL) derivatives.
  • polyethyleneimine-polyethyleneglycol-N-acetylgalactosamine PEI-PEG-GAL
  • PEI-PEG-triGAL polyethyleneimine-polyethyleneglycol-tri-N-acetylgalac-tosamine
  • nucleic acids can be administered and introduced by standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, by injection, or delivery by way of infection with a virus.
  • compositions of the present invention can also be formulated and used as tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions, suspensions for injectable administration, and the other compositions known in the art.
  • Liposomes containing poly (ethylene glycol) lipids offer a method for increasing the accumulation of drugs in target tissues. Such liposomes have been shown to accumulate selectively in tumors.
  • Administration routes that lead to systemic absorption include intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular routes. Each of these administration routes exposes the nucleic acids of the present invention to cells or tissue.
  • the nucleic acids of the present invention will generally be delivered at a pharmaceutically effective dose to prevent, inhibit the occurrence, or treat (so as to alleviate a symptom to some extent) a disease, condition or state.
  • the pharmaceutically effective dose depends on the type of disease or condition being treated, the composition used, the route of administration, the type of subject being treated, the physical characteristics of the specific subject under consideration, concurrent medication, and other factors that those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered.
  • nucleic acid molecules of the present invention can be administered orally, topically, parenterally, by inhalation or spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and/or vehicles.
  • parenteral includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or infusion techniques and the like.
  • the present invention also provides a pharmaceutical composition including a nucleic acid molecule of the invention and a pharmaceutically acceptable carrier.
  • a nucleic acid molecule of the invention can be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and if desired other active ingredients.
  • the pharmaceutical compositions containing nucleic acid molecules of the invention can be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
  • compositions intended for oral use can be prepared according to a suitable method known in the to the art.
  • the composition may contain one or more such sweetening agents, flavoring agents, coloring agents or preservative agents in order to provide a pharmaceutically acceptable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
  • excipients can be, for example, inert diluents; such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets can be uncoated or they can be coated by known techniques. In some cases such coatings can be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monosterate or glyceryl distearate can be employed.
  • Formulations for oral use can also be presented as hard gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions contain the active materials in a mixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents can be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate
  • the aqueous suspensions can also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • preservatives for example ethyl, or n-propyl p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
  • flavoring agents for example ethyl, or n-propyl p-hydroxybenzoate
  • sweetening agents such as sucrose or saccharin.
  • Oily suspensions can be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions can contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents and flavoring agents can be added to provide palatable oral preparations.
  • These compositions can be preserved by the addition of an anti-oxidant such as ascorbic acid
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerin, glycerin, glycerin, glycerin, glycerin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol
  • compositions of the present invention can also be in the form of oil-in-water emulsions.
  • the oily phase can be a vegetable oil or a mineral oil or mixtures of these.
  • Suitable emulsifying agents can be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions can also contain sweetening and flavoring agents.
  • Syrups and elixirs can be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions can be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated as known in the art using suitable dispersing or wetting agents and suspending agents that have been discussed previously.
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • Suitable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the nucleic acid molecules of the present invention can also be administered in the form of suppositories, e.g., for rectal administration of the drug.
  • suppositories e.g., for rectal administration of the drug.
  • These compositions can be prepared by mixing the nucleic acid with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the nucleic acid.
  • suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the nucleic acid.
  • Such materials include cocoa butter and polyethylene glycols.
  • the nucleic acid molecules of the present invention can also be administered parenterally in a sterile medium.
  • the nucleic acid depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
  • adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.
  • the composition can also be added to the animal feed or drinking water. It can be convenient to formulate the animal feed and drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It can also be convenient to present the composition as a premix for addition to the feed or drinking water.
  • nucleic acid molecules of the present invention can also be administered to a subject in combination with other therapeutic compounds to increase the overall therapeutic effect.
  • the use of multiple compounds to treat an indication can increase the beneficial effects while reducing the presence of side effects.
  • compositions of the present invention can also be formulated for administering the nucleic acid molecules of the invention to specific cell types.
  • receptors such as the asialoglycoprotein receptor are unique to hepatocytes and bind branched galactose-terminal glycoproteins, such as asialoorosomucoid.
  • some receptors such as the folate receptor are overexpressed in many cancer cells.
  • galactose, galactosamine, or folate based conjugates to transport exogenous compounds across cell membranes can provide a targeted delivery approach to, for example, the treatment of liver disease, cancers of the liver, or other cancers.
  • nucleic acid molecules of the present invention may also be complexed with or covalently attached to nanoparticles, such as Hepatitis B virus or L envelope proteins.
  • nucleic molecules of the present invention can be expressed within cells from eukaryotic promoters as previously discussed.
  • Viral vectors expressing the nucleic acids of the present invention may be constructed based upon, for example, adeno-associated virus, retrovirus, adenovirus, or alphavirus.
  • the viral vectors can either be use to introduce the nucleic acid into cells, or alternatively, the viral vector can be packaged and infections used to introduce the nucleic acids of the present invention to cells.
  • the viral vectors can provide for transient expression or stable expression of the nucleic acid molecules.
  • Viral and gene therapy techniques are as generally described in “Viral Vectors for Gene Therapy Methods and Protocols” Edited by Jules G Constant, Curtis A Machida (2003) Humana Press Inc., “Gene Delivery to Mammalian Cells: Viral Gene Transfer Techniques” Edited by William C Heiser (2004) Humana Press Inc., “Viruses in Human Gene Therapy” Edited by J. H. Vos (1995) Carolina Academic Press, and “Viral Therapy Of Human Cancers” Edited by J. G. Sinkovics and J. C. Horwath (2005) Marcel Dekker.
  • the present invention is also suitable for modulating the concentration of a nucleic acid in a cancerous cell or pre-cancerous cell.
  • an altered activity and/or concentration of a microRNA in a cancerous cell allows the concentration of the nucleic acid in the cell to be modulated by including in the nucleic acid a target site for binding of the microRNA.
  • the modulation of the concentration of the nucleic acid is as compared to a similar cell not having an altered activity and/or expression of the microRNA.
  • a reduced activity and/or concentration of a microRNA in a cancerous cell allows the concentration of the nucleic acid in the cell to be modulated by including in the nucleic acid a target site for binding of the microRNA.
  • the present invention also provides a method of modulating the concentration of a nucleic acid expressed in a cancerous cell, the cancerous cell having an altered activity and/or concentration of a microRNA as compared to a similar non-cancerous cell, the method including the step of introducing a target site for binding of the microRNA into the nucleic acid to be expressed in the cell.
  • nucleic acid a nucleic acid may be accomplished by a suitable method known in the art, such as Northern analysis, RT-PCR or RNase protection.
  • the present invention is also suitable for detecting an altered microRNA activity and/or concentration in a cancerous or pre-cancerous cell, such as a cancerous cell in vitro, or a cancerous or pre-cancerous cell in an animal or human.
  • a cancerous or pre-cancerous cell such as a cancerous cell in vitro, or a cancerous or pre-cancerous cell in an animal or human.
  • the cancerous cells and non-cancerous cells both express a reporter nucleic acid including a target site for binding of a microRNA, and an altered activity of the microRNA may be detected in the cancerous cells by determining the level of expression of the reporter nucleic acid in the cancerous and non-cancerous cells, and detecting a change in the activity of the microRNA in the cancerous cells by a change in the expression of the reporter nucleic acid in the cancerous cells as compared to the level of expression of the reporter nucleic acid in the non-cancerous cells.
  • the present invention is suitable for detecting a reduced microRNA activity and/or concentration in a cancerous or pre-cancerous cell.
  • a reduced activity of the microRNA may be detected in the cancerous cells by determining the level of expression of the reporter nucleic acid in the cancerous and non-cancerous cells, and detecting a reduced activity of the microRNA in the cancerous cells by an increase in the expression of the reporter nucleic acid in the cancerous cells as compared to the level of expression of the reporter nucleic acid in the non-cancerous cells.
  • the present invention provides a method of detecting altered microRNA activity and/or concentration in a cancerous or pre-cancerous cell, the method including the steps of:
  • the cancerous cells are present in an animal or human subject.
  • the non-cancerous cell may be the same or similar cells.
  • the cancerous (or precancerous cells) and the non-cancerous cells are both present in an animal or human subject.
  • the method may be used to detect a reduced activity of the microRNA by detecting an increase in the expression of the reporter nucleic acid in the cancerous cells as compared to the level of expression of the reporter nucleic acid in the non-cancerous cells.
  • the reporter nucleic acid in the cancerous (or pre-cancerous cells) is the same or a similar reporter nucleic acid as present in the non-cancerous cells.
  • reporter nucleic acids are known in the art.
  • the reporter nucleic acid may produce a detectable product such as LacZ, or GFP.
  • the reporter nucleic acid may be detected by an immunological detection method, with use of antibodies raised to the protein encoded by the reporter nucleic acid. Another method of detecting the reporter nucleic acid is by use of hybridization with a detectably labelled complementary nucleic acid probe.
  • Colorectal tumors and the corresponding normal mucosae may be obtained from fresh surgical resections, following informed consent from patients, and then classified according to standard histopathological classification methods.
  • RNA may isolated from cell lines, using Trizol reagent (Invitrogen, Carlsbad, Calif.) according to the manufacturer's instructions. RNA may be purified from colorectal tissues using the procedure of Chomczynski, P. and Sacchi, N. (1987). Anal. Biochem. 162: 156-159.
  • MicroRNAs miRNAs may be cloned essentially as described by Elbashir et al. (2001) Genes Dev. 15: 188-200, except that nucleic acids may be electroeluted from acrylamide gel slices using the Biotrap system (Schleicher and Schuell GmbH, Dassel, Germany). Briefly, small RNA fractions of between 18 and 26 bases may be size selected on a denaturing polyacrylamide gel. Adapter oligonucleotides, containing EcoRI restriction sites, may then be directionally ligated to the RNA molecules. The adapter-ligated RNA may then be amplified by RT-PCR.
  • Concatamerized fragments containing multimers of religated, EcoRI-digested PCR products, between 200 and 650 bp, are size selected on an agarose gel and recovered by electroelution. The concatamers may then be end-repaired and dA-tailed with Taq DNA polymerase, then cloned into pGEM T-easy (Promega, Madison, Wis.) or pTOPO (Invitrogen) according to the manufacturers' instructions. Plasmid inserts from the resultant colonies may be analyzed by PCR using primers to vector sequences.
  • nucleic acid sequence of selected inserts may then be determined following treatment of the PCR products with Exonuclease I and Shrimp Alkaline Phosphatase according to the ExoSAP-IT protocol (USB Corporation, Cleveland, Ohio). Clones created by this procedure will contain concatamers of PCR products, and generally likely to represent between two and five independent small RNAs.
  • RNA (20 ⁇ g) may be separated on a 15% denaturing polyacrylamide gel. Loadings are visualized by ethidium bromide staining. The RNA may then be transferred to Hybond N+ nylon membrane by semi-dry blotting (OWL Separation Systems, Portsmouth, N.H.). Probes may be generated by T4 Polynucleotide Kinase (New England Biolabs, Beverly, Mass.) mediated end-labeling of DNA oligonucleotides with [ ⁇ -32P]ATP.
  • the miRNA sequence may be concatamerized as a trimer of direct repeats, then cloned into pGEM T-easy and the insert amplified using PCR with M13 forward and reverse primers.
  • Antisense probes may then be synthesized using Taq polymerase-generated linear amplification from the Sephadex G-50-purified PCR products to incorporate multiple [ ⁇ -32P]dCTP bases.
  • Filter hybridization may be performed in QuikHyb Solution (Stratagene, La Jolla, Calif.) containing 10 6 cpm/ml probe for 1 h, with washes, as per the manufacturers' recommendations. Filters may be analyzed using a Fujifilm-BAS 2500 phoshorimager and signal intensity quantitated (as photostimulated luminescence/mm 2 ) using Analytical Imaging Station (version 3.0) software (Imaging Research Inc., Brock University, Ontario, Canada).
  • miRNA sequences may be identified by BLAST (as described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410) by comparison to the Genbank and EMBL public nucleotide databases. MicroRNAs may also be identified by comparison with the databases of the miRNA registry. The secondary structures of putative pre-miRNA hairpins may be determined using the Mfold 3.1 algorithm (as described in Mathews et al. (1999) J. Mol. Biol. 288: 911-940). Potential mRNA target sequences may be identified by searching the Genbank nonredundant and dbEST databases using BLAST and FASTA algorithms (as described in Pearson, W. R. and Lipman, D. J. (1988) Proc. Natl. Acad. Sci. USA, 85: 2444-2448) algorithms.
  • RNA fragments (between 18 and 27 bases) in total RNA, purified from both a colonic adenocarcinoma and its matched normal mucosa, may be size fractionated and cloned. The clones from the cancer-derived sample and clones representing normal mucosa may then be sequenced. Sequence analysis and comparison with public database nucleotide sequences will enable identification of many of the clones or assignment to a possible genomic origin for the transcripts.
  • Northern blot analysis may be undertaken against a panel of RNAs from matched colorectal cancer and normal mucosa specimens.
  • Northern blot analysis may be used to determine the levels of mature miRNAs and precursor hairpin molecules in cell lines derived from a variety of cancerous human tissues.
  • EGFP Enhanced Green Fluorescence Protein
  • pMM043 A mammalian Enhanced Green Fluorescence Protein (EGFP) expression cassette (pMM043; FIG. 2 ) was created by directionally inserting the EGFP coding sequence from pEGFP1 (Clontech) as a Bg/II/NotI fragment, into BamHI/NotI linearized pcDNA3.1(+) (Invitrogen).
  • the unique NotI and XbaI sites in the reporter gene 3′ untranslated region provided convenient sites for the insertion of miRNA-complementary and predicted in vivo target sequences.
  • pMM095 FIG.
  • a fragment of the pri-miR145 transcript was cloned by PCR amplification of the sequence corresponding to positions 184 and 734 of cDNA clone F1136638 fis (Genbank ID:21752921).
  • the oligonucleotides used were #556 (5′-TCCGGTACTTTTCAGGGCAA-3′; SEQ ID NO.4) and #557 (5′-CAAGAAACGCATGCCTGATG-3′; SEQ ID NO.5) in a standard PCR reaction using 50 ng HeLa genomic DNA as template with cycling conditions: 94° C. 3 minutes; 40 amplification cycles 94° C. 30 sec., 55° C. 30 sec., 72° C. 1 min; 72° C.
  • the 550 bp product was agarose gel purified and cloned into pGEMT-easy (Promega) to create plasmid pMM105.
  • the EcoRI insert of pMM105 (SEQ ID NO. 154) was then ligated into EcoRI linearised pcDNA3.1(+) (Invitrogen) to create the expression constructs: pMM109 (single sense insert; FIG. 8 ), pMM106 (single antisense insert; FIG. 6 ), and pMM107 (tandem sense inserts; FIG. 7 ).
  • the nucleotide sequence of pMM106 is provided in the sequence listing and is designated SEQ ID NO. 155.
  • the nucleotide sequence of pMM107 is provided in the sequence listing and is designated SEQ ID NO. 156.
  • the nucleotide sequence of pMM109 is provided in the sequence listing and is designated SEQ ID NO. 157.
  • Cotransfections of HeLa cells involved FuGene 6 (Roche)-mediated transfection of 0.1 ⁇ g of pMM095 with between 0.1 ⁇ g and 1 ⁇ g pri-miR145 expression vector (pMM109, pMM106, pMM107) in 24 well culture plates, using standard FuGene 6 (Roche) protocols.
  • EGFP activity was detected as direct fluorescence of live cells, 3 days following transfection, on a Typhoon fluorimager (Amersham Biosciences) and quantified using Imagequant software.
  • the miRNA, miR145 accumulates to only very low levels in HeLa (cervical carcinoma) cells. It was found that an enhanced Green Fluorescence Protein (EGFP) reporter gene construct containing the miR145 target sequence (from the RIGS transcript) is as active in these cells as an EGFP construct lacking the target sequence, as detected by fluorescence of the transfected cells.
  • EGFP Green Fluorescence Protein
  • a series of constructs will be created to contain combinations of the complementary target sequences for miR143 and miR145 in the 3′UTR of reporter genes (EGFP, LacZ, Renilla luciferase ) within constitutive expression vectors.
  • reporter genes EGFP, LacZ, Renilla luciferase
  • These vectors will include plasmids (for liposome mediated transfection and mouse transgenesis) and lentiviral systems.
  • MREs miRNA response elements
  • the EGFP construct described previously will be used, in conjunction with clones that contain several (up to four copies of the miR145 and miR143 complementary sequences), cloned into the NotI site of the 3′UTR.
  • LacZ constructs will be based on the synthetic, codon-optimised ⁇ -galactosidase sequence, described by Anson and Limberis (2004) J. Biotechnology 108: 17-30.
  • LacZ plasmid vectors will be based on the pcDNA3.1(+) expression backbone and that target sequences will also be inserted into the NotI site of the 3′UTR.
  • Luciferase constructs will be created using the psiCHECKTM-2 vector (Promega) by insertion of target sequences into the multiple cloning region in the 3′UTR of the synthetic Renilla luciferase gene.
  • the psiCHECKTM-2 vector also provides firefly luciferase as an internal control to normalise for transfection efficiency. Luciferase activities of transfected and transduced (in the case of lentiviral derivations) cells will be detected using the Dual Luciferase® Assay system (Promega) according to manufacturer's instructions.
  • results from experiments using the RIGS MRE in EGFP constructs show that the presence of miR145 will limit expression of foreign genes (that contain complementary 3′UTR sequences) in those cells.
  • a mammalian cell line that accumulates significant levels of mature miR143 or miR145 has not yet been identified.
  • a lack of miR143 accumulation in cell lines has also been reported by others and is postulated to be a consequence of the control of fundamental processes (such as proliferation) by these miRNAs.
  • dox-inducible miR145 HeLa cell lines will be produced to allow an investigation of the stoichiometry between miR145 levels and target sequences and the ability to silence gene expression. This will enable us to determine, in vitro, whether a threshold level of cytoplasmic miR145 is required to suppress reporter gene (EGFP, LacZ, luciferase) activity and cytotoxic gene (herpes simplex virus thymidine kinase) function.
  • reporter gene EGFP, LacZ, luciferase
  • cytotoxic gene herepes simplex virus thymidine kinase
  • Doxycycline-inducible pri-miR145 expression constructs were created by incorporating the PmeI insert from pMM106 (containing the pri-miR145 subfragment described earlier) to displace EGFP in the Tet-inducible expression cassette pMM060 between the unique Ascl (blunted) and PmII sites.
  • pMM060 utilises both the Tet-responsive promoter and tTR modified transrepressor described by Rossi et al. (1998) Nat. Genet. 20(4):389-93, with the transrepressor under the control of constitutive murine phosphoglycerate kinase regulatory sequences.
  • the construct with a single sense copy of the 550 bp pri-miR145 subsequence is called pMM110.
  • HeLa Tet-On cells (Clontech) have been stably-transformed with the pMM110 construct using FuGene 6-mediated transfection and following selection on both genticin and puromycin, clonal lines have been isolated. Different HeLa Tet-On/pMM110 lines display varying levels of pri-miR145 induction and mature miR145 accumulation, following 24 h exposure to 1 ⁇ g doxycycline/mL growth medium. The data is shown in FIG. 11 .
  • Normal intestinal mucosa, adenomatous and cancer tissues will also be obtained from the resections of consenting cancer patients and cultured as above.
  • Reporter gene constructs will be inserted into a lentiviral vector system as described in Anson and Fuller (2003) J. Gene Med. 5:829-838, and Fuller and Anson (2001) Human Gene Therapy 12: 2081-2093, and used to infect cultured explants.
  • the LacZ reporter gene will be replaced with the conditional cytotoxic gene, thymidine kinase, to determine whether MRE-derived tissue specificity is sufficient to selectively ablate tumour cells. Naturally, this will lead to the creation of constructs with tissue-specific promoters to enhance disease-specificity.
  • Transgenic mice will be created that express a LacZ reporter gene, containing multiple miR145 and miR143 complementary sequences in the 3′UTR, under the control of a constitutive promoter (CMV).
  • the transgene construct will also comprise a second reporter gene (EGFP) that does not contain such targeting sequences, but uses the same promoter.
  • Direct fluorescence or immunohistochemical detection of EGFP will define the tissue distribution of transgene expression while the subset of cells that also stain for LacZ activity will indicate those which are not affected by microRNA-mediated silencing.
  • Fluorescence will entail direct observation of fresh or paraformaldehyde-fixed tissues using an inverted fluorescence microscope. Fixed tissue may be pre-treated with 0.1% sodium borohydride, to reduce autofluorescence. GFP specific antibodies (Living Colours® Peptide Antibody; Clontech) will be used for immunohistochemical detection, using standard procedures.
  • Favourable transgenic mouse lines will be crossed with a p53 knockout mouse strain that is currently being used by the Young group to generate a murine model of colorectal cancer following administration of the carcinogen, azoxymethane (Hu et al. (2005) Int. J. Cancer 115: 561-567). The progeny of this cross will be examined for enhanced LacZ expression in tumour cells relative to surrounding epithelium.
  • founder lines will be assessed for low copy number insertion of the intact introduced expression cassettes and screened for appropriate expression of the transgenes using real-time RT-PCR and immunohistochemistry. Relative copy number determinations will be made using PCR of genomic DNA and/or Southern Blot analysis. Real time RT-PCR will utilize transgene mRNA-specific primers and cDNA templates in a 1 ⁇ SYBR green PCR Master Mix (Applied Biosystems) reaction. A Corbett Rotorgene 2000 (Corbett Research Pty. Ltd., Australia) will be used for PCR amplification and detection.
  • the final hybrid line will be inbred to ensure homozygosity for the transgenes, before cross-breeding with the p53 mutant mouse line and other murine models for cancer and polyposis.
  • MicroRNA target sequences in the 3′UTR of reporter and therapeutic genes will be used to assess the potential for exploiting tissue (or cell lineage)-specific microRNAs to limit transgene expression to defined cell lineages and tissues.
  • target sequences for the neural-specific miRNAs, miR124a and miR9 will be inserted into the 3′UTR of the EGFP or LacZ reporter genes.
  • a lentiviral delivery system will then deliver the synthetic gene into the genomes of murine embryonic stem cells.
  • Transduced embryonic stem cells will then be induced to differentiate into a variety of cells types, including neural progenitors (using the stromal-cell derived induction method of Kawasaki et al. (2000) Neuron 28: 31-40).
  • Reporter gene activity will be correlated with the expression of molecular markers to define which cell lineages allow expression of the introduced gene and which display miR9/124a-mediated silencing.
  • the transduced murine ES cells will be transferred into blastocysts to generate chimeric mice, from which stable transgenic germ lines will be generated (Pfeifer et al. (2001) Proc. Natl. Acad. Sci. USA 99: 2140-2145).
  • the spatial expression of reporter genes will be determined using direct detection (EGFP fluorescence or 3-galactosidase staining) or immunohistochemistry.
  • the data is shown in FIG. 12 .
  • the data demonstrates the Dox-inducible miR145 silencing of EGFP fluorescence in the transiently transfected cell line HT0110e, with the extent of silencing correlating with the number of miR145 target sequences present in the 3′UTR of EGFP.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Power Engineering (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Dc Digital Transmission (AREA)
  • Small-Scale Networks (AREA)
  • Remote Monitoring And Control Of Power-Distribution Networks (AREA)
  • Selective Calling Equipment (AREA)
  • Cable Transmission Systems, Equalization Of Radio And Reduction Of Echo (AREA)
  • Communication Control (AREA)
  • Computer And Data Communications (AREA)
  • Direct Current Feeding And Distribution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US11/916,276 2005-07-01 2006-06-02 Targeting cells with altered microrna expression Abandoned US20120190730A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2005A001248 2005-07-01
IT001248A ITMI20051248A1 (it) 2005-07-01 2005-07-01 Modem per bus per impianti elettrici civili ed industriali
PCT/AU2006/000750 WO2006128245A1 (en) 2005-06-03 2006-06-02 Targeting cells with altered microrna expression

Publications (1)

Publication Number Publication Date
US20120190730A1 true US20120190730A1 (en) 2012-07-26

Family

ID=36928649

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/916,276 Abandoned US20120190730A1 (en) 2005-07-01 2006-06-02 Targeting cells with altered microrna expression
US11/915,826 Expired - Fee Related US7965099B2 (en) 2005-07-01 2006-06-06 Bus modem for building and industrial electrical systems

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/915,826 Expired - Fee Related US7965099B2 (en) 2005-07-01 2006-06-06 Bus modem for building and industrial electrical systems

Country Status (20)

Country Link
US (2) US20120190730A1 (es)
EP (1) EP1900110B1 (es)
CN (1) CN101176269B (es)
AT (1) ATE463092T1 (es)
BR (1) BRPI0612368A2 (es)
CA (1) CA2607493A1 (es)
CR (1) CR9547A (es)
DE (1) DE602006013316D1 (es)
DO (1) DOP2006000264A (es)
ES (1) ES2342105T3 (es)
IL (1) IL183432A0 (es)
IT (1) ITMI20051248A1 (es)
MA (1) MA29307B1 (es)
MD (1) MD20070292A (es)
MX (1) MX2007012126A (es)
PL (1) PL1900110T3 (es)
PT (1) PT1900110E (es)
RU (1) RU2395162C2 (es)
SA (1) SA07270496B1 (es)
WO (1) WO2007003254A1 (es)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130157883A1 (en) * 2010-04-20 2013-06-20 Febit Holding Gmbh Complex miRNA Sets as Novel Biomarkers for an Acute Coronary Syndrome
US20130196869A1 (en) * 2011-12-29 2013-08-01 Quest Diagnostics Investments Incorporated Microrna profiling for diagnosis of dysplastic nevi and melanoma
CN104120128A (zh) * 2014-07-02 2014-10-29 重庆贝羿生物科技有限公司 一种用于促进vhl基因表达的分离的核苷酸分子和促进剂及其制备
US9457053B2 (en) 2012-11-30 2016-10-04 Accelerated Biosciences Corp. Methods of differentiating stem cells by modulating MIR-124
US9574173B2 (en) 2010-11-15 2017-02-21 Accelerated Biosciences Corp. Generation of neural stem cells from human trophoblast stem cells
US9808490B2 (en) 2014-11-26 2017-11-07 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
US10941403B2 (en) 2018-04-02 2021-03-09 Oregon Health & Science University Microrna inhibitors as anti-cancer therapeutics
US20220213481A1 (en) * 2020-04-02 2022-07-07 Mirecule, Inc. Targeted Inhibition Using Engineered Oligonucleotides
WO2023073661A3 (en) * 2021-11-01 2023-06-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing psd3 expression

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2339203B1 (es) * 2007-09-26 2011-02-10 Universidad De Las Palmas De Gran Canaria Aparato domotico compatible con los estandares celenec en 50090 e iso/iec 14543 para el control de camaras roboticas.
WO2011085703A1 (de) * 2010-01-12 2011-07-21 Gira Giersiepen Gmbh & Co. Kg Einrichtung und verfahren zum bereitstellen einer versorgungsspannung in einem busknoten eines busnetzes
EP2532129B1 (de) * 2010-02-05 2014-06-18 Gira Giersiepen GmbH & Co. Kg Empfänger in einem busknoten eines busnetzes
EP2541787B1 (en) * 2010-02-24 2019-12-11 Valery Vasilievich Ovchinnikov Method for transmitting discrete electric signals
DE102011122073B4 (de) 2011-12-19 2017-04-06 Dmos Gmbh Schaltung zur Stromversorgung von Baugruppen eines Bussystems
FR2996085B1 (fr) 2012-09-25 2014-09-26 Hager Controls Alimentation electrique a partir du bus pour un dispositif domotique
GB201315680D0 (en) * 2013-09-03 2013-10-16 Cooper Technologies Co Network power supply
CN104683118B (zh) * 2015-02-04 2017-11-14 合肥瑞纳表计有限公司 基于mbus的供电通讯装置及方法
US9654106B1 (en) * 2015-12-21 2017-05-16 Schneider Electric USA, Inc. Dynamic digital input filtering

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0824274B2 (ja) 1990-11-29 1996-03-06 松下電器産業株式会社 ホームバス電源分離・重畳回路
DK173291D0 (da) * 1991-10-14 1991-10-14 Ole Cramer Nielsen Datakommunikationssystem af feltbus-type, med et tolederkabel til baade stroemforsyning af tilsluttede enheder og dataoverfoering mellem disse
AU1726795A (en) * 1994-02-15 1995-08-29 Rambus Inc. Amplifier with active duty cycle correction
DE4424907A1 (de) 1994-07-14 1996-01-18 Siemens Ag Bordnetzversorgung bei Busankoppler ohne Übertrager
US5932976A (en) * 1997-01-14 1999-08-03 Matsushita Electric Works R&D Laboratory, Inc. Discharge lamp driving
DE59711867D1 (de) * 1997-01-21 2004-09-30 Siemens Ag Verfahren und Einrichtung zum übertragerlosen Ankoppeln einer Teilnehmerstation an einem Bus
US6788113B2 (en) * 2001-06-19 2004-09-07 Fujitsu Limited Differential signal output apparatus, semiconductor integrated circuit apparatus having the differential signal output apparatus, and differential signal transmission system
AT413908B (de) * 2002-08-12 2006-07-15 Siemens Ag Oesterreich Schaltwandler
US6853562B2 (en) * 2003-06-26 2005-02-08 Optimum Power Conversion, Inc. Voltage sense method and circuit which alleviate reverse current flow of current bi-directional converters
JP2005176620A (ja) * 2003-12-16 2005-07-07 Suzuhiro Kamaboko Honten:Kk 動物性タンパク質の分解物製造方法とその分解生成物を含む食品
EP1708548A4 (en) * 2004-01-22 2008-12-10 Matsushita Electric Works Ltd DEVICE FOR OPERATING A DISCHARGE LAMP, ILLUMINATOR AND PROJECTOR

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Johnson et al., 2005, Cell, Vol. 120(5), pgs. 635-647. *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611511B2 (en) * 2010-04-20 2017-04-04 Comprehensive Biomarker Center Gmbh Complex miRNA sets as novel biomarkers for an acute coronary syndrome
US20130157883A1 (en) * 2010-04-20 2013-06-20 Febit Holding Gmbh Complex miRNA Sets as Novel Biomarkers for an Acute Coronary Syndrome
US11254911B2 (en) 2010-11-15 2022-02-22 Accelerated Biosciences Corp. Generation of neural stem cells from human trophoblast stem cells
US9574173B2 (en) 2010-11-15 2017-02-21 Accelerated Biosciences Corp. Generation of neural stem cells from human trophoblast stem cells
US11891623B2 (en) 2010-11-15 2024-02-06 Accelerated Biosciences Corp. Generation of neural stem cells from human trophoblast stem cells
US20130196869A1 (en) * 2011-12-29 2013-08-01 Quest Diagnostics Investments Incorporated Microrna profiling for diagnosis of dysplastic nevi and melanoma
US10851424B2 (en) 2011-12-29 2020-12-01 Quest Diagnostics Investments Llc MicroRNA profiling for diagnosis of dysplastic nevi and melanoma
US20170081725A1 (en) * 2011-12-29 2017-03-23 Quest Diagnostics Investments Incorporated Microrna profiling for diagnosis of dysplastic nevi and melanoma
US11959143B2 (en) 2011-12-29 2024-04-16 Quest Diagnostics Investments Llc MicroRNA profiling for diagnosis of dysplastic nevi and melanoma
US9447471B2 (en) * 2011-12-29 2016-09-20 Quest Diagnostics Investments Incorporated Microrna profiling for diagnosis of dysplastic nevi and melanoma
US9988689B2 (en) 2011-12-29 2018-06-05 Quest Diagnostics Investments Incorporated Microrna profiling for diagnosis of dysplastic nevi and melanoma
US10053738B2 (en) * 2011-12-29 2018-08-21 Quest Diagnostics Investments Incorporated MicroRNA profiling for diagnosis of dysplastic nevi and melanoma
US11028366B2 (en) 2012-11-30 2021-06-08 Accelerated Biosciences Corp. Methods of differentiating stem cells by modulating MIR-124
US10294458B2 (en) 2012-11-30 2019-05-21 Accelerated Biosciences Corp. Methods of differentiating stem cells by modulating miR-124
US9457053B2 (en) 2012-11-30 2016-10-04 Accelerated Biosciences Corp. Methods of differentiating stem cells by modulating MIR-124
CN104120128B (zh) * 2014-07-02 2016-04-20 重庆贝羿生物科技有限公司 一种用于促进vhl基因表达的分离的核苷酸分子和促进剂及其制备
CN104120128A (zh) * 2014-07-02 2014-10-29 重庆贝羿生物科技有限公司 一种用于促进vhl基因表达的分离的核苷酸分子和促进剂及其制备
US10765704B2 (en) 2014-11-26 2020-09-08 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
US9808490B2 (en) 2014-11-26 2017-11-07 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
US11026979B2 (en) 2014-11-26 2021-06-08 Accelerated Biosciences Corp. Human hepatocytes and uses thereof
US10941403B2 (en) 2018-04-02 2021-03-09 Oregon Health & Science University Microrna inhibitors as anti-cancer therapeutics
US11795459B2 (en) 2020-04-02 2023-10-24 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
US11597930B2 (en) * 2020-04-02 2023-03-07 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
US20220213481A1 (en) * 2020-04-02 2022-07-07 Mirecule, Inc. Targeted Inhibition Using Engineered Oligonucleotides
US12104157B2 (en) 2020-04-02 2024-10-01 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
WO2023073661A3 (en) * 2021-11-01 2023-06-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing psd3 expression

Also Published As

Publication number Publication date
ES2342105T3 (es) 2010-07-01
RU2007138850A (ru) 2009-04-27
US20090016419A1 (en) 2009-01-15
SA07270496B1 (ar) 2011-04-05
PT1900110E (pt) 2010-07-01
PL1900110T3 (pl) 2010-09-30
CN101176269A (zh) 2008-05-07
DOP2006000264A (es) 2007-11-30
EP1900110A1 (en) 2008-03-19
EP1900110B1 (en) 2010-03-31
MA29307B1 (fr) 2008-03-03
US7965099B2 (en) 2011-06-21
CR9547A (es) 2008-03-07
CA2607493A1 (en) 2007-01-11
IL183432A0 (en) 2007-09-20
DE602006013316D1 (de) 2010-05-12
RU2395162C2 (ru) 2010-07-20
BRPI0612368A2 (pt) 2010-11-30
MX2007012126A (es) 2007-12-05
ATE463092T1 (de) 2010-04-15
ITMI20051248A1 (it) 2007-01-02
MD20070292A (ro) 2008-05-31
CN101176269B (zh) 2011-12-14
WO2007003254A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
EP2377559A1 (en) Targeting cells with altered microRNA expression
US20120190730A1 (en) Targeting cells with altered microrna expression
Li et al. MyoD-induced circular RNA CDR1as promotes myogenic differentiation of skeletal muscle satellite cells
Jin et al. miR-15a/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF-β signaling pathway
EP3426781B1 (en) Micrornas and methods of their use
Liu et al. LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells
Davis et al. SMAD proteins control DROSHA-mediated microRNA maturation
EP2550360B1 (en) Bivalent antisense oligonucleotides
US9567591B2 (en) Generation of human embryonic stem-like cells using intronic RNA
Shore et al. Noncoding RNAs involved in mammary gland development and tumorigenesis: there’sa long way to go
CN107365785B (zh) 一种调控细胞内NF-κB活性的基因表达载体及其调控方法和应用
EP2742127B1 (en) Inducable expression from the eukaryotic pol-2 promoter in prokaryotes
US20140221463A1 (en) Methods for heart regeneration
EP3191593A2 (en) Microrna inhibitor system and methods of use thereof
CN101641440A (zh) 用于调节靶rna活性的寡核苷酸
Jafarzadeh et al. Experimental evidences for hsa-miR-497-5p as a negative regulator of SMAD3 gene expression
US20070135368A1 (en) Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells
Orso et al. miR-21 coordinates tumor growth and modulates KRIT1 levels
Zhang et al. Identification of miR-2400 gene as a novel regulator in skeletal muscle satellite cells proliferation by targeting MYOG gene
Pham et al. MicroRNA gga-miR-10a-mediated transcriptional regulation of the immune genes in necrotic enteritis afflicted chickens
Kashyap et al. Transcripts for combined synthetic microRNA and gene delivery
Goes et al. Scratch2, a snail superfamily member, is regulated by miR-125b
Iovino et al. A loxP-containing pol II promoter for RNA interference is reversibly regulated by Cre recombinase
AU2004256322B2 (en) siRNA expression system
Zheng et al. LncRNA MIR144HG-derived miR-144 suppresses antibacterial signaling and facilitates bacteria escape in fish

Legal Events

Date Code Title Description
AS Assignment

Owner name: SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MICHAEL, MICHAEL ZENON;REEL/FRAME:020472/0921

Effective date: 20071214

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION